|Gyorgy Abel, MD, PhD||Lahey Hospital & Medical Center, Beth Israel Lahey Health|
Medical Director, Molecular Diagnostics, Pathology and Laboratory Medicine
Dr. Gyorgy Abel is the Medical Director of Molecular Diagnostics, Clinical Chemistry/Immunology, and Point of Care Testing at the Lahey Hospital & Medical Center in Burlington, Massachusetts. He also serves as Instructor in Pathology, Part-time, at Harvard Medical School. Gyorgy received his MD, and a PhD degree in immunology in Hungary, completed post-doctoral fellowship at the Brigham and Women’s Hospital, and residency at the Massachusetts General Hospital in Boston, and received board certifications in Clinical Pathology and Molecular Diagnostics. He made significant contributions to hepatitis C virus research by demonstrating the use of LDL receptor by the virus as a port of entry into hepatocytes. His professional interests include precision medicine and point of care testing. Gyorgy has held office in professional organizations such as the American Association for Clinical Chemistry (AACC), the College of American Pathologists, the American Association of Immunologists, and the Federation of American Societies for Experimental Biology, and currently he is President-Elect of the AACC Academy. He is also an Overseas Fellow of the Royal Society of Medicine, U.K.
|Daniel Adams||Creatv MicoTech Inc.|
Director, Clinical R&D
Daniel L. Adams is Director of Clinical R&D at Creatv MicroTech’s facility in NJ, focusing on development of custom assays and analysis of patient samples. He is credited with the discovery and phenotyping of circulating cancer associated macrophage-like cells (CAMLs). He has written extensively on the isolation, identification and clinical utility of CTCs, CAMLs, EMTs and circulating endothelial cells.
|Arushi Agarwal||Health Advances LLC|
Director, Precision Medicine
Arushi Agarwal joined the Health Advances team in 2011 and spends the majority of her time working in the Diagnostics and Life Sciences Practice. Her work focuses on global commercialization strategies for Precision Medicine diagnostics. Arushi’s specific areas of focus include companion diagnostics and liquid biopsy testing in oncology, as well as the intersection of Health IT solutions and diagnostic testing. Prior to joining Health Advances, Arushi received her Masters in Biomedical Engineering from Columbia University where her research focused on the use of microfluidic technologies for regenerative medicine applications. She received a Bachelors in Biology from the Massachusetts Institute of Technology.
|Pankaj Agarwal||BioInfi LLC|
Chief Computational Biologist
Pankaj Agarwal has 22+ years of strategic and tactical experience utilizing bioinformatics to enable drug discovery and create pipeline value. Dr. Agarwal has 50+ publications in top journals and multiple methodological and gene patents. Dr. Agarwal has served on NSF, NIH, FDA and PhRMA panels. He possesses a B.Tech. in Computer Science & Engineering from IIT, Delhi and a PhD in Computer Science from the Courant Institute of Mathematical Sciences at NYU. He is a founding director and senior member of the International Society for Computational Biology (ISCB). GSK Pharmaceuticals R&D appointed him a Senior Fellow in recognition of his internal and external achievements during his 22+ year tenure. At BioInfi, Dr. Agarwal serves as an advisor and strategic consultant to disease foundations and biotechnology companies including the Bill & Melinda Gates Foundation. Most importantly, Pankaj is passionate about drug discovery, data-driven solutions, and helping patients.
|Catherine Alix-Panabieres, PhD||Univ of Montpellier|
Director, Laboratory of Rare Human Circulating Cells (LCCRH), Pathology and Onco-Biology Department
Dr. Catherine Alix-Panabières received her PhD degree in 1998 at the Institute of Virology, University Louis Pasteur, in Strasbourg in France. In 1999, she moved to Montpellier where she did a postdoctoral research in the Department of Immuno-Virology of the University Medical Centre of Montpellier, France. During this last decade, Dr Alix-Panabières has focused on optimizing new techniques of enrichment and detection of viable disseminating tumor cells in patients with solid tumors. She is the expert for the EPISPOT technology that is used to detect viable tumor cells in the peripheral blood and the bone marrow of patients with breast, prostate, colon, head & neck cancer and melanoma. In 2010, she achieved getting a permanent position at the Hospital and at the Faculty of Medicine of Montpellier (MCU-PH), a wonderful mixture of giving teaching lessons to medical students on Cancer Biology in combination of developing this field of tumor cell dissemination at the hospital for the cancer patients, leading strongly translational clinical research. As an associate professor, she recently became the new director of the Laboratory of Rare Human Circulating Cells (LCCRH) in the Department of Cell & Tissue Biopathology of tumors. In this unique platform LCCRH, they isolate, detect and characterize circulating tumor cells using combinations of the EPISPOT assay, the CellSearch® system (Janssen), the flow cytometry, the CellCollector (GILUPI), the molecular biology (AmpliSpeed device), the Parsortix system and the DEPArray (Silicon Biosystem) for single cell sorting. She has authored or co-authored >50 scientific publications in this field during the last years including 10 book chapters and she is part of two big European projects: CTC-SCAN (Transcan project) and CANCER-ID (IMI project). After she got the Scientific Prize given by the Region Languedoc-Roussillon in 2008, it was a great honor for her to receive the Gallet et Breton Cancer Prize, the highest honor conferred by the French Academy of Medicine in November 2012.
|Ash Alizadeh, PhD||Stanford Univ|
Associate Professor of Medicine, Divisions of Oncology & Hematology, Stanford University School of Medicine
Dr. Alizadeh completed his PhD in Biophysics and MD at Stanford in 2003, under mentorship of Pat Brown (Stanford Biochemistry) and Lou Staudt (NCI/NIH). Supported by the Howard Hughes Medical Institute (HHMI) and NIH Medical Scientist Training Program (MSTP), he built the Lymphochip DNA microarray platform. He and his colleagues used this platform to profile gene expression in diffuse large B cell lymphoma (DLBCL), and many other tumors. This work led to the discovery of DLBCL subtypes, and a framework for their cell of origin. Following his clinical subspecialty Hematology and Medical Oncology training at Stanford, he completed his postdoctoral studies with Ron Levy and Irv Weissman. During this time, he worked on molecular outcome prediction in DLBCL, developing a statistical framework for identification of small numbers of genes for robust risk stratification and prognosis. Working with Irv Weissman, he identified CD47 expression as an adverse prognostic factor in non-Hodgkin lymphomas, and a therapeutic target of novel monoclonal antibodies that synergize to eradicate tumors. The Alizadeh lab studies genomic biomarkers of tumors, whether detected through biopsy of primary tissues, or non-invasively through monitoring blood using circulating tumor DNA (ctDNA). His group developed Cancer Personalized Profiling by deep Sequencing (CAPP-Seq) as a novel method for ctDNA detection and developed a novel cell deconvolution framework (CIBERSORT). His group applies such genomic tools for early detection, diagnosis, and monitoring of diverse tumors. In this effort, his group builds and employ tools from functional genomics, computational biology, molecular genetics, and mouse models.
|Jonathan Allen, PhD||ATOM Consortium|
Jonathan E. Allen has worked in bioinformatics research under the Science and Technology and Global Security programs for twelve years at Lawrence Livermore National Laboratory (LLNL). He leads an informatics team focused on modeling and managing data for complex biomolecular processes. He has extensive experience developing new software tools for pathogen characterization from complex biological samples, transcript analysis in host response and machine learning for small molecule drug discovery. Dr. Allen received his PhD in Computer Science from Johns Hopkins University in 2006, after conducting his thesis work at The Institute for Genomic Research (now The J. Craig Venter Institute).
|Leonela Amoasii, PhD||Exonics Therapeutics Inc|
Director Gene Editing Research, Vertex Genetic Therapies
No bio available
|Leigh Anderson||Premier Inc|
President of Performance Services
As the President of Performance Services, Leigh Anderson has overall responsibility for Premier’s Performance Services segment, including the continued development and growth of the company’s enterprise-wide, cloud-based informatics business, as well as Premier’s Performance Partners consulting unit. Anderson, who has more than two decades of informatics experience in corporate and provider settings, joined Premier in 2013. In his previous role as Chief Operating Officer for Information and Technology Services at Premier, Anderson ran the day-to-day operations of the informatics business. Prior to joining Premier, he served in lead informatics roles at Hospital Corporation of America, Health Trust, Global Healthcare Exchange (GHX) and AT&T. He received his bachelor’s degree in Industrial Engineering from Hofstra University, and his MBA from Wake Forest University. In addition, Leigh Anderson formerly served on the U.S. governing board of GS1.
|Bernard Andruss, PhD||Asuragen, Inc.|
SVP, Operations and Regulatory Affairs
Dr. Andruss joined Asuragen since its founding in March 2006. Bernard has significant R&D experience from his increasing responsibilities at Asuragen's predecessor, Ambion, Inc., where he helped initiate new R&D projects and expanded its SBIR funding program. During his tenure at Asuragen, Bernard was responsible for leading many successful diagnostic product development programs. Prior to Ambion, he worked in progressive roles at Rice University and the University of Texas M. D. Anderson Cancer Center.
|Kiana Aran, PhD||Keck Graduate Institute|
Assistant Professor, Medical Diagnostics and Therapeutics, Henry E. Riggs School of Applied Life Sciences
Kiana Aran received her undergraduate degree in electrical engineering at the City University of New York in 2007 and her PhD in biomedical engineering at Rutgers University in 2012. She then continued her postdoctoral studies in bioengineering at the University of California Berkeley and was a recipient of National Institutes of Health (NIH) postdoctoral training fellowship at the Buck Institute for Age Research in 2015. She joined KGI in January 2017 as an Assistant Professor. Since 2017, Aran has served as a Consultant for Drug Delivery and Medical Diagnostics for the Bill and Melinda Gates Foundation and is a cofounder of Nanosens Innovations Inc.
CEO & Co-Founder
Ardy Arianpour, CEO & Co-Founder of Seqster, is a visionary genomics executive and serial entrepreneur in the biotech industry. Prior to starting Seqster, Ardy launched several clinical and consumer-based genetic tests as CCO of Pathway Genomics and SVP of Ambry Genetics, which sold to Konica Minolta for $1B in 2017. He is one of the main architects in launching the first commercial clinical exome sequencing test in 2011, establishing the value of next-gen sequencing in the clinic. As a key player in the 2013 landmark SCOTUS decision scrapping gene patents, Ardy played an instrumental role in expanding genetic testing access with the launch of BRCA testing benefiting patients and family members across the country. Ardy received his BS in Biological Sciences from University of California Irvine and an MBA from Marshall Goldsmith School of Management.
|Ashish Atreja, MD, MPH||Icahn School of Medicine at Mount Sinai|
Assistant Professor, Chief Innovation Officer, Medicine
Dr. Atreja is a healthcare executive with board certification in internal medicine, gastroenterology and clinical informatics. As Chief Innovation Officer, Medicine, he leads the Sinai AppLab (http://www.applab.nyc) that is one of the first collaborative hub within academic medical center to build and test disruptive mhealth technologies. As an intrapreneur, Dr. Atreja has won innovation awards at Cleveland Clinic and Mount Sinai, successfully licensed technologies from academic centers and advises startups, accelerators and Fortune 500 companies in digital medicine. Dr. Atreja serves as Scientific Founder for Mount Sinai Spinoff, Rx.Health that brings first enterprise-wide app curation, prescription and engagement platform to risk sharing hospitals and payers in an affordable and scalable manner. Recently, Dr. Atreja established non-profit Network of Digital Medicine (NODE.Health) to connect innovation centers worldwide and share best practices for digital medicine innovation and implementation between industry, payers and health systems. Dr. Atreja has published more than 60 papers, presented more than 200 abstracts and has been a keynote speaker globally on topics related to digital medicine evidence and health system transformation. Dr. Atreja was nominated among the Top 40 HealthCare Transformers in 2017.
|Qingyan Au, PhD||NeoGenomics Laboratories, Inc.|
Principal Scientist, Pharma Services
Dr. Au is a Principal Scientist with the Pharma Services division at NeoGenomics, and has been working with the MultiOmyxTM platform for over 6 years. Prior to joining NeoGenomics she was a Staff Scientist at Sanford Burnham Prebys Medical Discovery Institute, and previous to that was a Research Scientist at CytRx Corporation. Dr. Au earned her PhD in Biomedical Sciences from the University of California at Riverside, and she also holds Master’s degree in Genetics from Fudan University. Dr. Au has authored/co-authored over 20 scientific publications and is a named inventor on 2 issued patents.
|Jonathan Baden, MS||Bristol Myers Squibb Co|
Jonathan Baden is a Director, Pharmacodiagnostics in the Bristol-Myers Squibb Translational Medicine organization. He joined BMS in September 2017 and supports evaluation, strategy, development and execution of the companion/complementary biomarker diagnostic programs for BMS that enhance value of the pharmaceutical product profiles. Jon leads a PDx matrix subteam to execute upon solid tumor and liquid biopsy NGS related strategies pertaining to patient selection (TMB/HRD) and disease monitoring (ctDNA). He provides strategic direction to business development led searches, evaluations and transactions for diagnostic partnering. In addition, Jon coordinates activities between the Development, Commercial teams and external diagnostic partners and is responsible for delivery of diagnostic partner critical milestones. Prior to joining BMS, Jon led diagnostic strategies aligned with therapeutic disease areas for the development of stand-alone and companion diagnostic at Janssen Pharmaceuticals and J&J subsidiaries. Jon led matrix teams both internally and with external partners for the management, execution and resolution of assay process for all stages of the product development life cycle. Jon has expertise in oncology disease states (prostate, bladder, lung, breast, and colorectal cancers), autoimmune diseases (Crohn’s and lupus) and infectious diseases (HIV, HCV, IFV, RSV, Ebola) and managed an exploratory NGS team and a late stage development team accountability for products on a fully integrated MDx platform. Jon received his MS degree in Microbiology from the University of Rochester School of Medicine and Dentistry working and also holds a BSc degree in Biotechnology from the Rochester Institute of Technology.
|Sudeep Basu, PhD||Frost & Sullivan|
Practice Leader, TechVision, Innovation Services
Dr. Sudeep Basu is a member of the global consulting practice at Frost & Sullivan. His interests include intellectual property, technology management, and business strategy. He is an inventor on patents while having published several peer reviewed journal and conference articles. Dr. Basu volunteers for BayBio and is an active member of the Silicon Valley chapter of The Indus Entrepreneurs (TiE). He was an AHA Pre-doctoral fellow at the Brown Cancer Research Center and is an alumnus of the Indian Institute of Technology (IIT), Bombay.
|Georg Bauer||STRATEC Consumables GmbH|
VP, Stratec Consumables GmbH in Salzburg. Head of the Development teams for customers in the markets life-sciences, IVD und MedTech. Realization of customers projects from prototyping to mass-manufacturing.
|Vipul Baxi, MS||Bristol Myers Squibb Co|
Principal Scientist, Digital Pathology Lead, Translational Bioinformatics
Vipul Baxi is a scientific leader with more than 10 years of experience in the medical device and life science industry, with a specific concentration on technical and clinical aspects of computational pathology and tissue-based biomarkers in immuno-oncology. He is currently a Principal Scientist and Digital Pathology Group Lead in Translational Bioinformatics at Bristol-Myers Squibb. In this role, he leads the digital pathology technology platform team in developing a robust & scalable pathology informatics infrastructure to augment biomarker discovery within the drug development process, and partner with latest advances in immunohistochemistry and artificial intelligence to uncover the next generation of computational biomarkers. Prior to this role, Vipul spent 7.5 years at Omnyx LLC, a joint venture between GE Healthcare and the University of Pittsburgh Medical Center that developed and commercialized diagnostic pathology solutions, holding positions with increasing responsibility within R&D and Clinical Research organization. Vipul earned his BS and MS in Biomedical Engineering from Rutgers University with a thesis focused on biomedical imaging instrumentation and image analysis.
|Kristin Beaumont, PhD||Icahn School|
Assistant Professor, Assistant Director of Single Cell Genomics Technology Development Icahn Institute, Dept. of Genetics & Genomic Sciences
Kristin received her PhD in Chemical Engineering from Arizona State University and pursued postdoctoral training in Chemical Biology, first at the University of Chicago and then at Northwestern University, where she focused on understanding and visualizing cellular adhesion and migration heterogeneity at the single cell level, particularly in the context of cancer metastasis. In 2015, Kristin joined Berkeley Lights, Inc. as part of their single cell assay R&D effort where she helped to develop and apply novel single-cell phenotypic assays and informatic approaches for a variety of collaborative investigations, including those focused on tumor heterogeneity. She returned to academia in 2017 when she joined the Icahn School of Medicine at Mount Sinai as an Assistant Professor of Genetics and Genomic Sciences and the Assistant Director of Single Cell Genomics Technology Development. As part of this role, she leads a wide range of single-cell and spatial genomic research collaborations that leverage novel technology, including those that are a continuation of her interest in understanding the role of genotypic and phenotypic heterogeneity in cancer.
|Michael Benecky, PhD||GlaxoSmithKline|
Senior Director, Global Regulatory Affairs, Precision & Digital Medicine
Mike received his BA in Biochemistry from the University of Wisconsin-Milwaukee and PhD in Biophysical Chemistry from Princeton University. Mike continued his academic research career as a Post-Doctoral Fellow at Northwestern University and as an Assistant Professor at the University of Wisconsin Medical School-Milwaukee Clinical Campus. Mike gained expertise in the preparation of FDA IDE and PMA medical device submissions for lasers used for vision correction surgery at Bio-Reg Associates. At QIAGEN (formerly Digene), Mike led the Regulatory /Clinical Affairs Group that prepared numerous FDA PMA submissions for the first FDA approved HPV DNA test for cervical cancer screening. Mike Benecky joined GSK in October 2011 as Senior Director, Global Regulatory Affairs in Precision and Digital Medicine located in Research Triangle Park, North Carolina. Mike currently assists GSK Teams in regulatory strategy during use of digital health technology in both clinical trial and commercial settings. Recent projects include the commercial launch of the MyAsthma mobile medical app in the EU and inclusion of digital sensors and mobile apps within GSK clinical development programs.
Global Head, PHC Imaging
Thomas Bengtsson joined Genentech in 2009, supporting clinical imaging in the Statistical Methods Group. Since 2017 he has led the Imaging Group within Roche Personalized Healthcare, focusing on AI solutions for imaging in drug development. He completed his PhD in Statistics in 2000 (University of Missouri, MO). He was a postdoc at National Center for Atmospheric Research, CO (2000–2003), the Neyman Visiting Professor in Statistics at the University of California, CA (2003–2005) and has worked at Bell Labs, NJ (2005–2009)
|Chantale Bernatchez, PhD||MD Anderson Cancer Ctr|
Assistant Professor, Melanoma Medical Oncology - Research, Cancer Medicine
My main interest is immunotherapy of cancer with a special emphasis on T cell therapy utilizing tumor infiltrating lymphocytes. My lab conducts translational research where human primary cells from cancer patients (tumors or immune cells) are interrogated to find markers of response to T cell therapy or other immunotherapies.
|Gregory Berry, PhD, D(ABMM)||Northwell Health Laboratories|
Director, Molecular Diagnostics, Assistant Director, Infectious Disease Diagnostics
Dr. Berry received his undergraduate degree in Biology from East Stroudsburg University in East Stroudsburg, Pennsylvania, and his PhD in Microbiology and Immunology from Pennsylvania State University College of Medicine in Hershey, Pennsylvania. He also completed a fellowship in Medical Microbiology and Public Health at University of Texas Medical Branch in Galveston, Texas. Dr. Berry is the Director of Molecular Diagnostics and an Assistant Director of Infectious Disease Diagnostics at Northwell Health Laboratories and is also the Director of Microbiology at Long Island Jewish Medical Center in New York. He is also a Diplomate of the American Board of Medical Microbiology and an Assistant Professor of Pathology and Laboratory Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. His interests include the optimization of current methodologies and the development of new technologies for patient-centered clinical testing.
|Shruthi Bharadwaj, PhD||Novartis Pharmaceuticals Corp|
Senior Scientist, Novartis Oncology Precision Medicine
Shruthi Bharadwaj is a Senior Scientist at Novartis within the Informatics and Analytics group. She received her PhD in Biomedical Engineering from the University of Florida and continued her research as a post-doctoral fellow at the MD Anderson Cancer Center. Shruthi has been interested and involved in utilizing AI and machine learning approaches in Pharma. She has a patent that involves machine-learning approach to predict the onset of colon cancer in patients with Inflammatory Bowel Disease. She has won several NIH grants that supported her research in leveraging AI approaches in healthcare. She has published several research articles, book chapters and abstracts that focus on AI approaches in diagnosis and drug development.
|Gabriel Bien-Willner, MD, PhD||Pamletto GBA|
Medical Director, Moldx
Dr. Bien-Willner is the Medical Director of the MolDX program at Palmetto GBA, a Medicare Administrative Contractor (MAC). MolDX seeks to understand the molecular testing landscape to implement payer controls, coverage, and to set policy for affiliated MACs, which currently cover 28 states. He is a leader in the Precision Medicine space and practices as a Board-certified Anatomic Pathologist and Molecular Genetic Pathologist. Throughout his career, he has been active in research, development, and advancement of molecular diagnostic services, specifically next generation sequencing. He has worked closely with clinicians to develop clear clinical diagnostic and treatment pathways directing Precision Medicine programs for community cancer centers. Dr. Bien-Willner received his MD and PhD degrees from Baylor College of Medicine, with a PhD in Human Molecular Genetics. He completed his residency, fellowship, and attained a faculty appointment at Washington University in St. Louis prior to leadership roles in laboratory and biotech companies before joining Palmetto GBA.
|Tim Blauwkamp, PhD||Karius|
Tim Blauwkamp is the Chief Scientific Officer and co-founder of Karius. Prior to Karius, he led research and lab operations for Moleculo until its acquisition by Illumina. Tim received his PhD in Biochemistry from the University of Michigan.
|Anne-Marie Boothman, PhD||AstraZeneca|
Diagnostics Director, Precision Medicine Unit
No bio available
|Kristine Bordenave, MD, FACP||Humana|
Former Corporate Medical Director
No bio available
|Bryan Bothwell||Qorvo Biotechnologies|
Director, Strategy and Business Development
Bryan Bothwell is Qorvo’s Director of Strategy and Business Development - with responsibility for new market, technology and customer development worldwide. He received undergraduate degrees in Biology/ Biochemistry, and Masters degrees in Electrical Engineering and Business Administration.
|Richard Bourgon, PhD||Genentech Inc|
Director, Senior Scientist, Oncology Bioinformatics
Richard is a Senior Scientist and is the Director for Oncology Bioinformatics at Genentech. He and his group pursue research in three major areas: (i) statistical and bioinformatics aspects of genomic data analysis, (ii) identification and application of genomic-assay biomarkers in the context of oncology clinical trials, and (iii) general characterization of the mechanisms of oncogenesis and drug resistance. A portion of the group specializes in problems in cancer immunology and immunotherapy, including molecular characterization of the tumor microenvironment and the use of tumor-specific neoantigens as biomarkers or as therapeutic targets. Richard obtained his PhD in Statistics at the University of California, Berkeley in 2006. He spent four years as a Staff Scientist at the European Bioinformatics Institute before joining Genentech in 2010.
|Scott Bratman, MD, PhD||Princess Margaret Cancer Ctr|
Radiation Oncologist, Radiation Medicine Program; Scientist, Princess Margaret Cancer Centre, University Health Network; Assistant Professor, Depts of Radiation Oncology and Medical Biophysics, University of Toronto
Dr. Scott Bratman is an Assistant Professor of Radiation Oncology and Medical Biophysics at the University of Toronto and serves as Clinician-Scientist and Staff Radiation Oncologist at The Princess Margaret Cancer Centre. Dr. Bratman was trained at Princeton University, Columbia University Medical Center, and Stanford Cancer Institute. Starting with his postdoctoral studies at Stanford, Dr. Bratman has developed cutting edge liquid biopsy technologies for detection and monitoring of cancer in the bloodstream. This work is revolutionizing cancer care by allowing cancer to be detected with a simple blood test. As a clinician-scientist, Dr. Bratman is at the front lines of translating liquid biopsies into improved health outcomes for patients. His research program has expanded to include lung cancer, cervix cancer, head and neck cancer, leukemia, among others. His work has been recognized through publication in high impact scientific journals such as Nature, Nature Medicine, Nature Biotechnology, and JAMA Oncology. The Bratman Lab strives to be a source of innovation and novel technologies for next-generation blood-based biomarkers.
|Jillian Buchan, PhD||Stanford University|
Clinical Assistant Professor, Pathology
Jillian is a board-certified Clinical Molecular Geneticist working in Stanford Medicine’s Clinical Genomics Program (CGP). She completed a research-based MS at University College Dublin in Ireland and later received her PhD in Molecular Genetics and Genomics in 2014 from Washington University in St. Louis. After her PhD, Jillian joined Harvard Medical School's Genetics Training Program and completed her fellowship in Clinical Molecular Genetics in 2016. Jillian then joined the Department of Pathology at Stanford School of Medicine and became board-certified by the American Board of Medical Genetics and Genomics in 2017. Her focus is on molecular-based diagnostic testing, with the majority of her time spent in the CGP, where she oversees overall laboratory operations, development of new next-generation sequencing-based clinical assays, ensures CAP/CLIA regulatory compliance, and signs out clinical test reports. She and her team launched Stanford's first clinical exome sequencing test, and the first test for the newly created CGP, in early 2018.
|Kris Buchanan||Phase Three Product Development|
Kris Buchanan is the CEO and founder of Phase Three Product Development. He is a biomedical and systems engineer who has worked in all phases of product development for over 30 years. Kris is also the inventor or co-inventor of more than 75 USPTO and international patents. Kris has a history of building and leading product development teams and even R&D divisions of large companies and had an extensive network of engineers, assay developers, and other technical specialists. At Phase Three, he has assembled an all-star team of experienced engineers and scientists with pre-built communication systems and an understanding of competencies.
|Benjamin Busby, PhD||NIH NLM|
Scientific Lead, NCBI Hackathons Program, Computational Biology Branch
Generation of clustering algorithms for analysis of large gene families and whole genomes
Phylomic Analysis of Gene Transfer Events
|Susan Butler-Wu, PhD, D(ABMM)||LAC+USC Medical Center|
Associate Professor of Clinical Pathology, Keck School of Medicine, University of Southern California, Director of Clinical Microbiology
Dr. Butler-Wu received her Doctorate of Philosophy in Molecular Microbiology from Tufts University in 2005. Following her completion of a postdoctoral fellowship in bacterial pathogenesis at NYU, she subsequently completed a post-doctoral fellowship in Medical and Public Health Microbiology at the University of Washington, Seattle. Dr. Butler-Wu continued her career at the University of Washington where she was Associate Director of the Clinical Microbiology Laboratory and an Assistant Professor in the Department of Laboratory Medicine. She recently joined the faculty at the University of Southern California as an Associate Professor in Clinical Pathology and is also Director of Clinical Microbiology at LAC+USC Medical Center. Her research interests include the development and application of diagnostic methods for the rapid detection of infection and antimicrobial resistance, as well as improved diagnostic methods for the detection of prosthetic joint infections caused by Propionibacterium species. Dr. Butler-Wu is a Diplomate of the American Board of Medical Microbiology.
|Atul Butte, PhD, MD||Univ of California San Francisco|
riscilla Chan and Mark Zuckerberg Distinguished Professor; Director, Bakar Computational Health Sciences Institute, University of California, San Francisco; Chief Data Scientist
Atul Butte, MD, PhD is the Priscilla Chan and Mark Zuckerberg Distinguished Professor and inaugural Director of the Bakar Computational Health Sciences Institute (bchsi.ucsf.edu) at the University of California, San Francisco (UCSF). Dr. Butte is also the Chief Data Scientist for the entire University of California Health System, with 17 health professional schools, 6 medical centers, and 10 hospitals. Dr. Butte has been continually funded by NIH for 20 years, is an inventor on 24 patents, and has authored over 200 publications, with research repeatedly featured in the New York Times, Wall Street Journal, and Wired Magazine. Dr. Butte was elected into the National Academy of Medicine in 2015, and in 2013, he was recognized by the Obama Administration as a White House Champion of Change in Open Science for promoting science through publicly available data.
|Juan Caicedo, PhD||Broad Institute|
Schmidt Fellow, Principle Investigator
Juan Caicedo is a Schmidt Fellow at the Broad Institute of MIT and Harvard, where he investigates the use of deep learning to analyze biological data. Previous to this, he studied object detection problems in large scale image collections with deep reinforcement learning at the University of Illinois in Urbana-Champaign. Juan received a PhD from the National University of Colombia and completed research internships in Google Research, Microsoft Research, and Queen Mary University of London as a grad student, working in problems related to large scale image classification, image enhancement, and medical image analysis. His research interest include computer vision, machine learning and computational biology.
|Rachael Callcut, MD, MSPH||Univ of California San Francisco|
Program Director, Smarter Health Artifical Intelligence Initiative
Rachael A. Callcut, MD, MSPH is an Associate Professor of Surgery at the University of California San Francisco. She also is the Director of Data Science for the UCSF Center for Digital Health and the Program Director of the UCSF SmarterHealth Artificial Intelligence Initiative. Dr. Callcut is double board certified in General Surgery and Critical Care maintaining an active clinical practice in trauma and critical care at UCSF and Zuckerberg San Francisco General Hospital. Dr. Callcut’s efforts with the Center for Digital Health Innovation are focused on leading a multi-disciplinary team working at the intersection of artificial intelligence to drive change in the delivery of healthcare for both patients and providers. Dr. Callcut also directs a multidisciplinary NIH and DOD funded research lab focused on integration of data science into critical care for improved clinical decision support. In addition to her active clinical practice, she is the founder and director of the Trauma, Injury Science, and Critical Care Collaborative (TRISECT) research group at UCSF.
|Roberta Carbone, PhD||Tethis S.p.A|
Roberta Carbone graduated in Pharmacy, then spent two years at the NIH (USA); she attained a PhD in Forensic Medicine and worked as Researcher at the European Institute of Oncology (IEO) in Milan, where she focused her research in innovation in the biomedical field. She is author of more than 30 publications in peer-reviewed international journals and several patent applications. She joined Tethis for the development of innovative diagnostic approaches in oncology based on Tethis proprietary nanomaterials.
|Lon Castle||eviCore healthcare|
Chief Medical Officer, Molecular Genetics and Personalized Medicine
Dr. Lon Castle is responsible for the clinical performance of the Laboratory Medicine and Specialty Drug programs at eviCore healthcare. He has been working in the genomic and molecular diagnostic field for over a decade, designing and implementing programs that support personalized medicine initiatives that bring additional precision to the healthcare decisions facing physicians and their patients. Previously, Dr. Castle worked as the Medical Director for Managed Care at CardioDx where he was responsible for discussing the science of their proprietary genomic test to detect coronary artery disease to payers. He also collaborated with payers on projects and program designs to demonstrate the clinical value of the test. As part of the Medical Affairs team, Dr. Castle was also involved in developing the clinical and health economic study designs. Before CardioDx, Dr. Castle was employed at Medco Health Solutions (now Express Scripts) as the Senior Director for Clinical Innovation. During his 12 years there he worked on numerous projects, including the initial development of the company’s personalized medicine testing programs, demonstration projects with pharmaceutical manufacturers to establish the value of genetic markers for novel medications and publication of the organization’s annual Drug Trend Report. Dr. Castle received his undergraduate degrees in Biology and English from Bucknell University in Lewisburg, PA. He received his medical degree from the Medical College of Ohio in Toledo. He completed his residency in Family and Community Medicine at the Medical Center of Delaware in Wilmington and his Sports Medicine fellowship at The Ohio State University in Columbus. Dr. Castle practiced sports medicine for over a decade at the Baylor College of Medicine and the Baylor Sports Medicine Institute in Houston, TX, serving as team physician for numerous professional, college and high school sports teams.
David Cavanaugh is a partner at DeciBio with over 15 years of combined experience in life science business consulting and academic and corporate life science research and development. David has extensive experience assisting medical device clients with market assessments, opportunity identification, product / franchise expansion strategies, growth strategy development, and new product developments. A recent example included a WW market assessment in the medical diagnostics space where his VOC research and analysis identified key customer requirements and actions the client could take to better compete with existing and new product offerings. Prior to DeciBio, David worked for six years as a Senior Manager at L.E.K. Consulting where he managed multiple ongoing lifescience engagements at a time. Prior to that, David worked for seven years as a computational biologist at leading organizations, including Genentech and GlaxoSmithKline. David received his MBA from the Kellogg School of Management at Northwestern University with a focus in international strategy, biotechnology and healthcare and his BS in Chemical Engineering from UVA.
|Yu-Feng Chan, MD, PhD||Otsuka Pharmaceutical Dev & Commercialization Inc|
Dr. Chan is Senior Director, Medical Affairs for Digital Medicine, Otsuka. Dr. Chan was the principal investigator for the Mount Sinai Asthma Mobile Health Study using the Asthma Health app powered by Apple’s ResearchKit framework. This pioneering virtual study of >10,000 participants from 3 countries demonstrated that a broad scale clinical study could be conducted in its entirety via a smartphone application, including remote participant recruitment, consent, prospective collection of data including geolocation, environmental and device data, as well as secure bi-directional data exchange between participants and investigators. Recently, Dr. Chan and her digital health team created and deployed a digital platform to scale Mount Sinai’s recruitment and engagement of the institution’s DNA biobank research participants. Additionally, she is also the Mount Sinai principal investigator for the NIH U01 “Practice-Based Research to Improve Self-Management Support (PRISMS) Sensor Development Projects for Pediatric Asthma study”- an innovative smartphone and biosensor device research collaboration with the Center for Bioelectronics and Biosensors at Arizona State University and University of Southern California.
|Hsueh-Chia Chang, PhD||Univ of Notre Dame|
Bayer Corporation Professor of Chemical Engineering, Chemical and Biomolecular Engineering
Prof Chia Chang, the Bayer Professor of Engineering and Director of the Center for Microfluidics and Medical Diagnostics, is a leading researcher in micro/nanofluidics, particularly in the area of nano-electrokinetics. He has just published a Cambridge Univ Press book on the subject. His group combines analysis and physical insight to discover new physical phenomena and to develop patented devices for technology transfer. More than 20 of his former PhD students are now teaching in leading academic universities throughout the world. Prof Chang is the founding Editor of Biomicrofluidics, an American Institute of Physics journal. He has received many awards including the Frankiel Award from the American Physical Society and the Presidential Young Investigator Award from NSF. A fellow of APS, he has delivered more than 20 keynote/plenary lectures and has more than 200 publications with over 3000 citations.
|Jie Cheng, PhD||AbbVie|
Director, Exploratory Statistics
Dr. Jie Cheng received his PhD in Computer Science in 1998 and completed his postdoctoral training in AI & Machine Learning in 2000. He has more than 15 years of experience in applying machine learning and predictive modeling to clinical and biomarker data analysis. Dr. Cheng is a director at Abbvie, leading biomarker and exploratory analysis in immunology and neuroscience projects.
|Adrian Chernoff||Johnson & Johnson|
Former Worldwide Vice President, Global Head of Research and Development
Adrian Chernoff, BSM.E., MBA, M.E.M.E. is a visionary technologist and digital transformation executive who helps companies create and deliver what comes next. Honored with 20 awards and 90 patents, he routinely solves critical business problems to deliver game-changing products and first-to-market solutions. Distinguished career encompasses 20+ years of leading innovation, fostering collaboration, building new capabilities, leveraging insights from other industries, influencing change and introducing new products and services within companies, across industries and around the world. An experienced builder and strategist of new digital platforms, patient-centric mobile apps and smarter medical devices that empower millions of patients and improve patient outcomes. As Worldwide Vice President, Global Head of R&D, Digital and Innovation for the Johnson and Johnson $2B Diabetes Care Companies he launched IoT connected medical devices, deployed a digital health platform ecosystem and introduced the #1 diabetes app in the U.S. and available in 20 countries with over 1M downloads to help patients better manage their diabetes.
|Charles Chiu, MD, PhD||UCSF School of Medicine|
Professor, Laboratory Medicine and Medicine/Infectious Diseases, Director, UCSF-Abbott Viral Diagnostics and Discovery Center, Associate Director, UCSF Clinical Microbiology Laboratory
Dr. Charles Chiu, MD, PhD, is a Professor in Laboratory Medicine and Medicine, Infectious Diseases at the University of California, San Francisco. He is also the Director of UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC) at China Basin and Associate Director of the UCSF Clinical Microbiology Laboratory. Charles is an expert in the emerging field of clinical metagenomics, and his research is focused on the development and validation of microarray and next-generation sequencing (NGS) technologies for viral discovery and pathogen diagnostics, with over 20 patents and peer-reviewed publications on these topics. In addition, he is the principal investigator of a 5-year R01 grant from the NIH on multiplexed blood bank pathogen screening, California Discovery, UC-MEXUS, and National Research Fund for Tickborne Diseases (NRFTD) grants on the microbial epidemiology of encephalitis, diarrhea, and Lyme disease, a QB3 Rogers Family Foundation Award in translational diagnostics, and a UCSF-Abbott Viral Discovery Award. Charles is also an active practicing infectious diseases physician at UCSF. Charles has active collaborations with research groups and public health agencies worldwide, including Abbott Diagnostics, Inc., Blood Systems Research Institute, the California Department of Public Health, the United States CDC, the American Red Cross, and the Texas Biomedical Research Institute.
|Joshua Coleman, MD||ARUP Labs|
Assistant Professor, Pathology, Medical Director for Molecular Oncology
Dr. Coleman is an assistant professor of pathology at the University of Utah School of Medicine and director of genomics for the Division of Anatomic Pathology at ARUP Laboratories. He earned his MD at Case Western Reserve University School of Medicine in Cleveland, OH, in 2007. Dr. Coleman subsequently completed his residency in anatomic and clinical pathology at the Cleveland Clinic (2011), followed by fellowships in hematopathology at the University of New Mexico (2012) and molecular genetic pathology at ARUP Laboratories/University of Utah (2013). He is board-certified in molecular genetic pathology, hematopathology, and anatomic and clinical pathology, practicing most recently at the Ohio State University (2013-16). Immediately prior to joining the University of Utah, Dr. Coleman served as the vice president of medical affairs with GenomOnocology, LLC, in Cleveland, Ohio. His academic interests include leveraging machine learning techniques to facilitate interpretation of genomic data.
|Mark Connelly||Menarini Silicon Biosystems|
Chief Industrial Operations, R&D Officer
No bio available
|Ryan Copping, PhD||Genentech Inc|
Global Head of Analytics, PHC Data Science, Personalized Healthcare (PHC), Product Development
No bio available
|Andy Coravos||Elektra Labs|
CEO & Co-Founder
Andy Coravos is a software engineer and the CEO/co-founder of Elektra Labs, which is building a pre-competitive digital biomarker consortium, and a Fellow at Boston Children’s Computation Health Informatics Program. Andy interned as a software engineer at Akili Interactive Labs, a leader in digital medicine and digital biomarkers while in grad school. Before grad school, she worked at KKR, a private equity firm, and McKinsey & Company, a management consulting firm, where she focused on the healthcare industry. She writes about healthcare, software/tech, digital biomarkers, the attention economy, and more on her blog.
|Jennifer Couch, PhD||National Cancer Institute|
Chief, Structural Biology and Molecular Applications Brand, Division of Cancer Biology and Citizen Science Coordinator
Jennifer Couch, PhD, is the Chief of the Structural Biology and Molecular Applications Branch in the Division of Cancer Biology, NCI, NIH. Dr. Couch’s branch supports research and development of enabling technologies and methodologies including structural biology and biophysical characterization; bioinformatics, computational biology, mathematical modeling, data science, citizen science and crowdsourcing methods, and systems biology; molecular applications including synthetic biology; and bioengineering and biotechnology including biomimetics. Dr. Couch serves as the co-Lead for the Cancer Moonshot Technology Development Implementation Team which aims to accelerate basic, clinical and epidemiological cancer research through the development and validation of experimental and in silico technologies. Additionally, she as the NIH Citizen Science and Crowdsourcing Coordinator which explores the use of and potential for citizen science approaches to biomedical research and provides resources to the research community. She leads efforts in data analysis, software development and novel approaches to Biocomputing for the NIH Big Data to Knowledge Program. She acts as the computational biology coordinator for the NCI Cancer Systems Biology Consortium, managing the mathematical modeling program and co-leads a program which bridges the gap between cancer mechanism and population out-comes. She works on several NIH Common Fund initiatives including Single Cell, Library of Integrated Cell Signatures, and Biocomputing. In addition, Dr. Couch participates in several trans-NIH and trans-agency efforts and has helped to organize workshops and programs in areas such as Quantitative Systems Pharmacology, Multi-Scale Modeling, and Games for Biomedical Research.
|Dana Crawford, PhD||Case Western Reserve Univ|
Associate Professor, Department of Population and Quantitative Health Sciences
Dr. Crawford’s laboratory accesses large-scale epidemiologic and clinical data in electronic health records to characterize common and rare genetic variants associated with human diseases. A particular interest is in identifying pleiotropy (when a single gene influences two or more seemingly unrelated physical traits) and environmental modifiers of genetic associations, including pharmacogenomics (the study of how genes affect a person’s response to drugs). She has published more than 160 peer-reviewed manuscripts. Among her accomplishments was serving as principal investigator of the NIH’s Electronic Medical Records & Genomics (eMERGE) Network Coordinating Center and co-chair of the eMERGE Network’s Genomics Working Group. She also played a leadership role in the NIH’s Population Architecture using Genomics and Epidemiology (PAGE) study. She is currently serving a three-year term as an elected member of the American Society of Human Genetics Board of Directors. In addition to her primary research, Dr. Crawford promotes the cultivation of women and minorities in STEM education and research by organizing and participating in national and international workshops and educational lectures, that emphasize participation and perspectives or women and minorities. She is an advocate for diversity in research design and cohort recruitment, recognizing that perspectives and findings from diverse studies can unlock why people with diverse genetic, behavioral, and environmental backgrounds can have varied outcomes to interventions or treatments. Her honors and awards include the Case Western Reserve University School of Medicine Faculty Diversity Award, Society for Advancement of Chicanos and Native Americans in Science Distinguished Research Mentor Award, Kavli Frontiers of Science Fellow, Keystone Symposia on Molecular and Cellular Biology Fellow, NCMHD/NIH Health Disparities Research Scholar, and the ASHG C.W. Cotterman Award. Before coming to CWRU, Dr. Crawford spent eight years as tenure-track faculty in the Department of Molecular Physiology and Biophysics and Investigator in the Center for Human Genetics Research at Vanderbilt University.
|Briony Cristiano, PhD||Minifab|
As Head of Bioscience, Briony oversees the translation of biological assays and systems onto Minifab’s microfluidic platforms. Briony has over 11 years industry experience, with 4 years based in the USA working in the highly regulated medical device / in vitro diagnostic (IVD) field developing immunodiagnostics.
|Michelle Crouthamel, PhD||AbbVie Inc|
Director, Digital Health & Innovation
No bio available
|Nirav Dalal||Abbott Labs|
Senior Director, Data Science & Analytics
Nirav Dalal leads the Global Data Science and Analytics function at Abbott medical devices. He has more than twenty years of experience in the medical device industry. Nirav is interested in methods and tools to improve healthcare and create value using “Big Data” and machine learning. He received an MS in Electrical Engineering from California Polytechnic State University, San Luis Obispo and an MBA from Pepperdine University. He has published more than fifty peer-reviewed journal articles, conference abstracts, and US patents. He is a frequent speaker on medical devices, real-world evidence, digital health, health economics, and data science. His past speaking engagements include talks at the FDA, AdvaMed, Big Data in Healthcare, American Chamber of Commerce, Medical Design & Manufacturing, Global Cardiovascular Clinical Trialists Forum, and numerous other conferences.
|Patrick Daugherty, PhD||Serimmune, Inc.|
CSO and Founder
Patrick Daugherty is the Chief Scientific Officer of Serimmune. Daugherty received his BS in Chemical Engineering from The University of Minnesota in 1993, and his PhD from the University of Texas at Austin in 1999. He was a Research Fellow at the Fred Hutchinson Cancer Research Center in Seattle during 1999-2001, before joining the Chemical Engineering faculty at UCSB in 2001. At UCSB, Daugherty was promoted to Associate (2005) and full Professor (2008), and served on the faculty until 2015. He is the recipient of a National Sciences Foundation Career Award (2005), Camille Dreyfus Teacher Scholar Award (2006), and the Genentech Young Investigator Award from the ACS Division of Biochemical Technology (2007). Daugherty co-founded CytomX Therapeutics, Inc. (2008) – Nasdaq:CTMX serving as CSO from 2008-2010. Daugherty founded Serimmune Inc. in 2014, where he served as President and CEO from 2014-2019. Daugherty was elected to the American Institute of Medical and Biological Engineering (AIMBE) in 2011, honoring the top 2% of bioengineers. Daugherty’s research and work is focused on the development of methods to map serological antibody repertoires to their antigens.
|Jennifer Davids||Menarini Silicon Biosystems|
Director, Field Scientific Support
Dr. Jennifer Davids has a degree in Immunogenetics from the University of Florida and has spent recent years supporting molecular research in cancer and genetics.
|Kevin Davies, PhD||CRISPR Journal|
Kevin is the author (or co-author) of three popular science books exploring the medical and societal impact of advances in DNA sequencing and analysis. Kevin’s debut book (co-authored with Michael White) -- Breakthrough: The Race to Find the Breast Cancer Gene -- examined the fierce rivalry to isolate the BRCA1 gene. Cracking the Genome: The Race to Unlock Human DNA (Free Press, 2001) was the first published account of the Human Genome Project saga and was translated into 16 different languages. The $1,000 Genome: The Revolution in DNA Sequencing and the New Era of Personalized Medicine (Free Press, 2010) considered the advances in DNA sequencing and consumer genetics. Coming soon: Kevin is the co-author with Nobel laureate Jim Watson of an updated edition of DNA: The Story of the Genetics Revolution (Knopf, August 2017). A native of London, Kevin studied biochemistry at the University of Oxford and took a PhD in molecular genetics from St. Mary’s Hospital Medical School (University of London), where he worked on mapping the cystic fibrosis gene. After postdoctoral fellowships at MIT and Harvard Medical School, Kevin hung up his lab coat for good and moved into science publishing, joining the editorial staff of Nature. Within two years, he was named the founding editor of Nature Genetics, the world’s leading genetics research journal, which debuted in 1992, establishing the template for a string of successful spin-off journals. Kevin has held several prominent editorial and publishing positions since then, including Editor-in-Chief of Cell Press, the flagship journal division of Elsevier, and launch editor for Bio-IT World, a sister magazine to Macworld covering big data in the life sciences. Kevin has also worked at the Howard Hughes Medical Institute and the American Chemical Society, the world’s largest scientific society, where he was publisher of the Society’s weekly magazine Chemical & Engineering News.
|Jeffrey Davis||Brand New Day|
|Justin Wade Davis||AbbVie Inc|
ACOS Research Fellow, Director, Computational Genomics, Genomics Research Center (GRC)
Wade Davis is Director and Research Fellow in the Genomics Research Center at AbbVie, where he leads a group of computational scientists working to solve complex problems in genomics as it relates to pharmaceutical discovery and development. The team is responsible for analyzing genomic data from AbbVie clinical trials and external sources, such as Genomics Medicine Ireland, FinnGen, and UK Biobank. These data involved exceeds over 1 million subjects and provide a rich source of data for biopharma research.
Wade holds undergraduate degrees in Mathematics and Economics from Armstrong State University and PhD in Statistics from University of Missouri, where he also completed an NIH fellowship in Bioinformatics. He has been funded on dozens of federal research grants and served on the editorial board for the Journal of the American Statistical Association. After a 12 year career in academia at Baylor University and University of Missouri School of Medicine where he was an tenured Associated Professor, he joined the pharmaceutical industry.
|Ashleigh Dawley, RAC||ICON plc|
Manager, Regulatory Affairs, Medical Device and Diagnostic Research
Ashleigh Dawley is an experienced Regulatory Professional specializing in in vitro diagnostic (IVD), companion diagnostic (CDx), and medical devices. Ashleigh’s expertise spans the complete product lifecycle including feasibility, R&D, study design, quality control, regulatory strategy of complex products through global submission preparation/approval, as well as marketing and commercialization strategies from a regulatory perspective.
|David Deetz||Ativa Medical|
David Deetz is a founder and CTO of Ativa Medical. Previously he founded two other medical device companies, one of which completed a successful IPO on NASDAQ and was identified by Deloitte as one of the fastest growing medical device companies in the nation. The other was acquired by Danaher/Radiometer and has become an important part of their POC product line. He also founded an artificial intelligence company which was the first AI application to get broad adoption by financial services companies. He has authored 11 U.S. patents and raised approximately $140 million in private and public capital for his companies.
|Thomas Defay||Alexion Pharmaceuticals Inc|
Senior Director, R&D Strategy and Alliances, SPMD, Strategy, Program Management and Data Sciences
Tom received his PhD from the University of California San Francisco. He started his career in bioinformatics and data science, eventually leading teams in genomics, and molecular sciences. He then transitioned to project management, project leadership and portfolio management, ultimately taking on the role of chief of staff for the neuroscience research area. Two years ago, Tom joined Alexion to lead a number of alliances with the goal of increasing the ability to diagnose children with rare diseases. Recently, the alliance with the Rady Children’s Institute for Genomic Medicine and CliniThink led to a record-setting patient diagnostic effort.
|Paul Denny Gouldson||Zifo RnD Solutions|
Chief Digital Officer, Digital Solutions
Paul has worked at Zifo since late 2019 and is helping to define new service offerings, customer solutions, and partners. Prior to this, he joined IDBS in 2005 as part of acquisition of his ELN company and where he spearheaded the drive to make E‑WorkBook Suite the market leader. Prior to this, Paul founded a number of companies focused on combining science, technology, and business. Paul obtained his Ph.D. in Computational Biology from Essex University.
|Gini Deshpande, PhD||NuMedii, Inc.|
Founder & CEO
A molecular biologist by training, Gini has more than 16 years of experience turning cutting-edge scientific concepts into products that benefit patients. As CEO of NuMedii, Gini structured the company’s critical partnerships with some of the world’s largest pharmaceutical companies including Allergan, Astellas and Aptalis, and raised the initial rounds of financing. Before NuMedii, she helped companies identify optimal markets and whole-product solutions for their groundbreaking technologies, including Affymetrix and iPierian, and led innovation at Children’s Hospital Boston, where she focused on the creation of new devices for the tiniest of patients. Gini has helped commercialize early-stage technologies in research tools, diagnostics and therapeutics and has closed licensing deals worth several million. She received her MS from the University of Pune (India), her PhD in Biological Sciences from Purdue University, and did post-doctoral work at the Massachusetts General Hospital.
Chief Health Informatics Officer, Principal
Asif is a principal in Deloitte Consulting LLP's Monitor Deloitte practice. He serves as Chief Health Informatics Officer (CHIO) and helps drive the Therapeutic Area Transformation Integrated offering. He is a thought leader on topics such as comparative and clinical effectiveness, exponentials and innovation, personalized medicine, informatics, and disease transformation. He has a deep understanding of the complexities of clinical data reuse for safety, quality, and outcomes.
|Lorella Di Donato, PhD||Caprion Biosciences|
Senior Vice-President, Chief Operating Officer
Lorella Di Donato is leading the global scientific operations at Caprion Biosciences, Inc., overseeing the immune monitoring, proteomics, bioinformatics, and project management groups. Her scientific expertise includes assay development and validation for the analysis of biomarkers and drug products. She has validated over 200 assays and was instrumental in their deployment, from exploratory to primary endpoints, combining technical, scientific and regulatory requirements. She has been actively involved in regulatory audits for over twenty years.
|Lisa Diamond||Pinpoint Sciencem Inc.|
Pinpoint cofounder and CEO Lisa Diamond has a 40-year track record of technology innovation and senior engineering management, from pioneering development in molecular diagnostics and computational genomics to financial and trading applications, business intelligence and analytics, computer animation, digital video and more. She has collaborated with Dr. Pourmand over the last fifteen years to develop novel molecular diagnostics for pathogens including pandemic influenza, human papilloma virus, and drug-resistant TB, and holds two patents for novel molecular diagnostics. Diamond was principal software and systems architect with San Francisco non-profit Global Viral. As systems architect and developer at the Stanford Genome Technology Center for ten years, she built software to generate molecular probes for colon and esophageal cancer, pandemic influenza, drugresistant TB, and human papilloma virus, and developed novel software to analyze the vaginal microbiome. Other software innovation at startup Pathogenica focused on panels of multiplexed probes to identify pathogens and characterize resistance and virulence. As VP of Engineering at Black Pearl, she led development of innovative AI business applications. Lisa led streaming wireless and data visualization development for equity trading as VP of Technology Innovation at Reuters, and led the Market Data Engineering team at their Tibco Finance Technology division in Palo Alto. Prior to that, as vice president of Architecture and Strategy for Global Market Data Systems at Merrill Lynch, she was responsible for key trading floor infrastructure and applications in Tokyo and New York. Earlier in her career, Lisa pioneered groundbreaking real-time graphics, animation and digital video systems.
|Jennifer Dien Bard, PhD, D(ABMM)||Children’s Hospital Los Angeles; University of Southern California|
Director, Microbiology and Virology, Pathology and Laboratory Medicine
Jennifer Dien Bard, PhD, D(ABMM) is the Director of the Clinical Microbiology and Virology Laboratory at Children¹s Hospital Los Angeles and an Associate Professor with Clinical Scholar designation at the University of Southern California, Keck School of Medicine. Dr. Dien Bard’s research interest include studying the applications of rapid diagnostics in the clinical setting to determine clinical utility. She is a frequent speaker on the topics of rapid molecular diagnostics.
|Kuan-Fu Ding||Catalytic Data Science|
Chief Science Officer
Kuan-Fu Ding is currently the Chief Science Officer at Catalytic Data Science. Until recently he was the Chief Technology Officer at Cubismi Inc. Earlier, as Chief Science Officer of Sapiens Data Science, Kuan led all aspects of the company’s science-related research, development, and solutions, including product strategy, bioinformatic and data analysis workflows, and technical support for commercial and operational functions. He worked closely with other company leaders to ensure effective use of diverse data sources, cost-effectiveness, and continuous improvement to achieve overall company success. Prior to joining Sapiens, Kuan was a Senior Data Scientist at Intrexon, where he pioneered data science and computational biology efforts in the health therapeutics division. He successfully created a scientific team dedicated to the application of bioinformatics, machine learning, and artificial intelligence algorithms in health. Kuan received a PhD in Bioinformatics and Systems Biology from the University of California, San Diego, a MSc in Biostatistics from the University of Virginia, and a BSc in Mathematics from the University of Texas at Austin.
|Ray Dorsey, MD||Univ of Rochester|
avid M. Levy Professor, Neurology; Director, CHeT
Dr. Ray Dorsey is the David M. Levy Professor of Neurology and Director of the Center for Health + Technology at the University of Rochester. Through creative use of technology, he and his colleagues seek to enable anyone anywhere to receive care, participate in research, and benefit from therapeutic advances. Dr. Dorsey previously directed the movement disorders division and neurology telemedicine at Johns Hopkins and worked as a consultant for McKinsey & Company. His research has been published in leading medical, neurology, and economic journals and has been featured on National Public Radio, in The New York Times, and in The Wall Street Journal. In 2015, the White House recognized him as a “Champion for Change” for Parkinson’s disease.
|Shivang Doshi||Boston Healthcare|
Shivang Doshi has worked with a variety of pharmaceutical and diagnostics clients on issues related to market access, evidence development and reimbursement strategies of novel diagnostic technologies. His specific areas of expertise include value-based molecular assays, companion diagnostics, and informatics tools that support the delivery of precision medicine.
|Brian Dougherty, PhD, MBA||AstraZeneca Pharmaceuticals|
Executive Director, Translational Science, Oncology IMED
Brian is the Executive Director of Translational Genomics Oncology at AstraZeneca Pharmaceuticals in Boston, MA, leading AstraZeneca’s cancer genomics efforts. He oversees a team of lab scientists and computational biologists applying leading-edge genomic and advanced algorithmic technologies to deliver on Precision Medicine - matching the right patient with the right drug. This includes biomarker development, patient selection and monitoring strategies, identifying new tumor drug resistance mechanisms, researching genetics-based translational hypotheses, and delivering novel cancer targets. When he was previously at Bristol-Myers Squibb, Pfizer, TIGR and Amgen, Brian led sequencing, genotyping, gene expression, high-content imaging, and functional genomics lab efforts, applying technologies to enable the discovery and development of medicines for diseases such as cancer, infectious diseases, chronic pain, and Alzheimer’s Disease. Brian holds a BA from the University of Delaware, a PhD from Wake Forest University Medical Center, an MBA from the University of New Haven, and completed a postdoctoral research fellowship in the laboratory of Nobel laureate Hamilton O. Smith at The Johns Hopkins University School of Medicine.
|Nicholas Dracopoli, PhD||Delfi Diagnostics|
Nicholas (Nic) Dracopoli, PhD is Chief Scientific Officer at DELFI Diagnostics, a seed stage cancer diagnostics company based in Baltimore, MD. Previously he led oncology translational science teams at Bristol-Myers Squibb and Janssen. Prior to joining the pharmaceutical industry, he spent several years in the biotechnology industry at Sequana Therapeutics. Nic obtained his bachelor’s degree and doctorate from the University of London and completed postdoctoral fellowships at the Memorial Sloan-Kettering Cancer Center in New York City, NY and the Massachusetts Institute of Technology (MIT) in Cambridge, MA. Subsequently, he served as an Assistant Director at the Whitehead/MIT Genome Center and as a Section Chief at the National Center for Human Genome Research at the National Institutes of Health. Nic has authored more than 70 scientific publications and has extensive experience in the fields of genomics, molecular biology and cancer research.
|Jose Duca, PhD||Novartis Institutes for Biomedical Research Inc|
Global Head, Computer-Aided Drug Discovery
No bio available
Digital Tech Arch Principal Director
Carl Dukatz, Digital Tech Arch Principal Director, Accenture
Carl Dukatz leads the Quantum Computing Program at Accenture, focused on helping clients explore and seize the potential of quantum computing. As a part of this initiative, Carl directs quantum computing R&D, partnerships, and client pilots, including the design and development of applied quantum applications aimed at delivering near-team business value across a wide range of industries. Sample applications include pharmaceutical drug discovery, financial services portfolio analysis, supply chain optimization, and electrical grid load balancing.Carl has extensive research experience in the data platform space, including Big Data, modern data acceleration patterns, data processing pipelines / workflows, ingestion/munging/transformations, governance of data lakes, real rime analytical models, containerization and analytics at the edge. Prior to his work at Accenture Labs, Carl managed teams in Accenture’s Security Cyber Threat and Vulnerability Management group, testing for IT infrastructure weakness and creating protection strategies for large clients. Carl holds a Bachelor’s in Telecommunications from Michigan State University and is a Certified Information Systems Security Professional (CISSP).
|Rob Dumanois||Thermo Fisher Scientific|
Manager Reimbursement Strategy, Clinical Next-Generation Sequencing Division
Rob leads reimbursement strategy for Thermo Fisher’s Oncomine™ Dx Target Test: the first FDA-approved next-generation sequencing (NGS) in vitro diagnostic test for non-small cell lung carcinoma (NSCLC). This companion diagnostic, now covered by Medicare’s NCD and dozens of commercial payers, was developed with Pfizer and Novartis. Prior to joining Thermo Fisher in 2012, Rob played key payer and commercial roles with Navigenics, RelayHealth, and UnitedHealthcare.
|Chris Dwan||Independent Life Sciences Consultant|
Since 2017, Chris Dwan has been an independent consultant, technologist, and leader in scientific computing and data architecture for the life sciences. Since striking out on his own, he has worked with dozens of companies, including universities, research institutes, biotechs, pharmaceuticals, and government agencies. From 2014 to 2017 Dwan directed the research computing team at the Broad Institute. He was instrumental in the development of Broad’s program in data sciences, as well as its transition from on-premise to a hybrid cloud infrastructure. He served as Acting Director for all of Broad IT during Broad’s yearlong search for a new CIO. Chris was the first technologist at the New York Genome Center, from its inception in 2011 through 2014. He architected, designed, and built all of the computing, data storage, and network infrastructure for NYGC, including substantial renovations to its Manhattan headquarters. In this role he reported to the executive director and presented regularly to the board of directors. Chris was the first full time employee of the Boston based consulting firm, BioTeam. Between 2004 and 2011 he designed and deployed solutions for dozens of customers, who were at all stages of adopting and leveraging technology for genomic science. Along the way, he helped to build BioTeam into one of the best known and most respected consulting organizations in the industry. By the end of his tenure, he was the manager of consulting services, and served on the Board of Directors alongside the founders. Chris’s academic background is in computer science, with a specialization in machine learning and artificial intelligence. His work with neural networks in the late ’90s contributed to a pragmatic and grounded skepticism that has served him well through wave after wave of emerging technologies.
|Christopher Dwan||Individual Consultant|
Since 2017, Chris Dwan has been an independent consultant, technologist, and leader in scientific computing and data architecture for the life sciences. Since striking out on his own, he has worked with dozens of companies, including universities, research institutes, biotechs, pharmaceuticals, and government agencies.
From 2014 to 2017 Dwan directed the research computing team at the Broad Institute. He was instrumental in the development of Broad’s program in data sciences, as well as its transition from on-premise to a hybrid cloud infrastructure. He served as Acting Director for all of Broad IT during Broad’s yearlong search for a new CIO.
Chris was the first technologist at the New York Genome Center, from its inception in 2011 through 2014. He architected, designed, and built all of the computing, data storage, and network infrastructure for NYGC, including substantial renovations to its Manhattan headquarters. In this role he reported to the executive director and presented regularly to the board of directors.
Chris was the first full time employee of the Boston based consulting firm, BioTeam. Between 2004 and 2011 he designed and deployed solutions for dozens of customers, who were at all stages of adopting and leveraging technology for genomic science. Along the way, he helped to build BioTeam into one of the best known and most respected consulting organizations in the industry. By the end of his tenure, he was the manager of consulting services, and served on the Board of Directors alongside the founders.
Chris’s academic background is in computer science, with a specialization in machine learning and artificial intelligence. His work with neural networks in the late ’90s contributed to a pragmatic and grounded skepticism that has served him well through wave after wave of emerging technologies.
|Zahra Eftekhari||City of Hope|
Senior Manager, Head of Applied AI and Data Science
Nasim is a Data Scientist leading predictive analytics and clinical decision support efforts at City of Hope Center for Informatics. Her area of focus is application of machine learning and Artificial Intelligence (AI) to real-time monitoring, risk assessment and management of adverse events for oncology patient population. Outside City of Hope, Nasim advises many startup companies on technology and roadmap for successful implementation of AI solutions. Before joining City of Hope, Nasim co-founded Aistra Inc, an AI company that leveraged publically available social media, political and financial markets data to make predictions and recommendations regarding stock and commodity markets. Nasim holds a Master’s degree in Computer Science and a Bachelor’s degree in Computer Engineering.
|Nasim Eftekhari, PhD||City of Hope Medical Foundation|
Senior Manager, Head of Applied AI and Data Science
No bio available
|Kenneth Emancipator, MD||Merck & Co Inc|
Executive Medical Director, Companion Diagnostics & Translational Medicine
Ken led Merck’s translational program which developed the “PD-L1 test,” defined the “TPS 50” tumor, and revolutionized the treatment of non-small cell lung cancer. The PD-L1 test, commercialized by Agilent, became the first FDA-approved companion diagnostic for immunotherapy, enabled Keytruda (pembrolizumab) to become “first to first line,” and thereby helped countless patients live longer. The translational program continued to advance cancer immunotherapy, and PD-L1 now is a companion diagnostic for Keytruda in six tumor types. Keytruda has become the foundation of Merck’s oncology program, Merck’s top-selling drug, and the leading anti-PD-1 drug in the industry (having begun 4-5 years behind its major competitor). In recognition of his contribution to patients and to the advancement of cancer immunotherapy, Dr. Emancipator received the 2019 Israel Davidsohn Distinguished Service Award and the 2017 Philip Levine Award for Outstanding Research from the American Society for Clinical Pathology (ASCP). He was one of 6 individuals to receive, on behalf of Merck, the 2015 PhRMA Research and Hope Award for research by a biopharmaceutical company. Dr. Emancipator received his AB degree from Harvard University and his MD from St. Louis University. He completed his medical internship at Westchester County Medical Center and his pathology residency at the State University of New York at Stony Brook. He has held appointments at the US National Institutes of Health, the US Food and Drug Administration, Cornell University, Beth Israel Medical Center, Bayer Healthcare, Siemens Healthcare, and Abbott Molecular prior to joining Merck. He also has held various leadership positions with ASCP, eventually becoming its Treasurer and serving on its Board of Directors. He is reviewer for the American Journal of Clinical Pathology.
|James Fackler, MD||Johns Hopkins Medicine|
Director, Pediatric Critical Care Medicine, Associate Professor of Anesthesiology and Critical Medicine
Dr. Fackler’s clinical work is pediatric critical care and anesthesiology at Hopkins. Before taking his current role at Hopkins in 1996, he was on the faculty of the Harvard Medical School where he co-founded the Children’s Hospital Informatics Program. He worked for the Cerner Corporation from 2002 to 2006 and was responsible for the development and deployment of their critical care solution suite. His academic interests are the harnessing of the data generated by, and about, critically ill children for use in identifying and reducing the clinician driven variability in the care of complex conditions (such as sepsis). He founded a startup, Rubicon Health, an early-stage startup and believes every child (or patient more broadly) deserves their health care (e.g., critical care) delivered with precision. We create and maintain clinical team support software, so the teams consistently deliver high value care. Our first solution provides Clinical Team Support Solution for sepsis* care assisting the bedside team from early detection through management. Rubicon, merges clinical expertise and AI in all processes to anticipate, treat and manage sepsis. As a platform built by clinicians for clinicians, we understand the needs of sepsis care.
|Maria Fardis, PhD, MBA||Iovance Biotherapeutics|
President & CEO
Dr. Fardis has extensive experience in drug development and novel cancer treatments. Prior to joining Iovance Biotherapeutics, Dr. Fardis was chief operating officer at Acerta Pharma working on the development of CALQUENCE® (acalabrutinib), until the company’s acquisition by AstraZeneca. Before joining Acerta, Dr. Fardis held the position of chief of oncology operations and alliances at Pharmacyclics where she oversaw development of IMBRUVICA® (ibrutinib). She was a key contributor in the creation of a broad clinical program for ibrutinib, as well as NDA and MAA submissions. Previously, Dr. Fardis held a number of key scientific and management roles at Gilead Sciences. At Gilead, she was involved with multiple therapeutic areas including antivirals, oncology, and cardiovascular therapeutics and worked on the development and life cycle management of LETAIRIS® (ambrisentan). She received her PhD in organic chemistry from UC Berkeley and holds an MBA.
|Helen Fernandes, PhD||Columbia Univ|
Co-Director Genomic Oncology, Laboratory of Personalized Genomic Medicine
Helen Fernandes PhD, is an Associate Professor of Pathology in the Department of Pathology and Cell Biology and the Co-director of Genomic Oncology in the Personalized Genomic Medicine Laboratory, at Columbia University Medical Center. She has over 20 years of experience in molecular pathology focused on validation and implementation of clinical NGS assays and has inspected clinical laboratories nationally and internationally. Dr. Fernandes is involved in the training and education of molecular diagnosticians and has presented at meetings and webinars nationally and internationally. She is an active member of several organizations including, Association for Molecular Pathology (AMP) and American Association for Clinical Chemistry (AACC).
|Joseph Ferrara||Boston Healthcare|
President & CEO
Joe Ferrara has over 20 years of experience in life sciences consulting, working with biopharmaceutical, medical device, diagnostics, and informatics clients in market and business development strategy. Mr. Ferrara has extensive experience in the development of novel business approaches designed to capture evidence-based value for innovative healthcare technologies.
|Kyle Fieleke||Klaris Diagnostics|
Vice President, Business Development & Marketing
Kyle joined Klaris Diagnostics as VP of Business Development & Marketing in April 2018. He brings deep clinical diagnostics industry expertise and over 15 years of experience in health technology strategy and commercialization. Kyle comes to Klaris from Luminex Corporation where he most recently served as Sr. Director, Global Strategic Marketing. There he developed numerous key partnership and led many aspects of the company’s strategic investments into its high-growth molecular diagnostics franchise. Prior to joining Luminex, Kyle held marketing, sales and consulting positions with Abbott Laboratories and Cerner Corporation. Kyle holds a BS in Finance and a BA in Music from Truman State University and an MBA from the Kellogg School of Management at Northwestern University.
|Jeff Fill||Eli Lilly and Company|
Senior Director, Diagnostic and Experimental Pathology, Lilly Research Laboratories
Jeff Fill is the Senior Director in Diagnostic and Experimental Pathology at Eli Lilly. With over 25 years of experience in clinical biomarker laboratories Jeff has extensive experience developing and implementing biomarker solutions for clinical trial support. Spanning from research grade to IVD level development efforts, he utilizes a unique risk-based quality system to validate, verify or qualify assays and instruments to support Therapeutic Drug Team requirements. Jeff is a military veteran who received his BS in Medical Technology from Indiana University in 1993, MBA from Kelly School of Business (Indiana University) in 2011 and Lean Six Sigma Black Belt in 2012.
|Shirin Ford||Daiichi Sankyo Inc|
Head, Precision Medicine, Clinical Biomarkers & Companion Diagnostics
No bio available
|Kristen Fortney, PhD||BIOAGE Labs|
Kristen leads BIOAGE in its mission to develop a broad pipeline of therapies that target aging in order to increase healthspan and address chronic diseases. Kristen draws from a deep background in aging research and systems biology to develop BIOAGE’s data-driven approach to identify and target the molecular pathways that drive aging. Kristen received her PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford University where she was a fellow of the Ellison Medical Foundation / American Federation for Aging Research. She has over 10 years of experience developing novel bioinformatics approaches for data-driven investigation into the mechanisms of aging and age-related disease, with 18 published papers spanning computational drug discovery, biomarkers of aging, and the genetics of exceptional human longevity.
|Brian Fritz, PhD||10 X Genomics|
Associate Director, AMR Regional Marketing
No bio available
|Birgit Funke, PhD, FACMG||Harvard Medical School|
Vice President, Clinical Affairs, Veritas Genetics; Associate Professor, Pathology
Birgit Funke, Vice President of Clinical Affairs, a board-certified clinical molecular geneticist, and also an Associate Professor of Pathology at Harvard Medical School. Dr. Funke focuses on genetic testing with emphasis on genetically heterogeneous inherited diseases, with further specialization in cardiomyopathies, myopathies, and congenital cardiovascular malformations. Her main goals are to pave the way for implementing clinical exome sequencing as a universal first-line test, to improve curation of genetic knowledge, and to work towards automation of knowledge-driven decision support for interpreting and reporting genetic test results. In addition, she is interested in facilitating clinical genome-wide reporting for common, complex disorders and pharmacogenetic traits.
|Larissa Furtado, MD||St Jude Childrens Research Hospital|
Medical Director, Molecular Pathology, Pathology
No bio available
|Anna Füzéry||Alberta Public Laboratories|
North Sector POCT Medical Lead
Anna Füzéry obtained her PhD in biochemistry from the University of Wisconsin-Madison, and subsequently completed a 2-year postdoctoral training program in clinical chemistry at Johns Hopkins Medical Institutes in Baltimore, MD. She accepted a position as clinical chemist for Alberta Health Services in 2013, where she oversaw high volume general chemistry testing at 11 laboratories in Edmonton, Alberta. She became medical lead of point-of-care testing (POCT) for Edmonton in 2017, and for the northern half of the province of Alberta in 2019. Her current interest is in enabling high quality, clinically relevant POCT in mobile health care environments.
|Nils Gehlenborg||Harvard Medical School|
Nils Gehlenborg received his PhD from the University of Cambridge and was a predoctoral fellow at the European Bioinformatics Institute (EMBL-EBI). The goal of Gehlenborg’s research is to improve human health by developing computational techniques and interfaces that enable scientists and clinicians to efficiently interact with biomedical data. Tight integration of algorithmic approaches from biomedical informatics with advanced data visualization techniques is central to his efforts, as is close collaboration with clinicians and experimentalists. Currently, Gehlenborg is researching and developing novel tools to visualize heterogeneous data from large-scale cancer genomics studies such as The Cancer Genome Atlas, integrating visual and computational approaches to support sense-making in biology, and using software to support reproducible collaborative research in epigenomics and genomics. Gehlenborg is a co-founder and former general chair of BioVis, the Symposium on Biological Data Visualization, and co-founder of VIZBI, the annual workshop on Visualizing Biological Data. Occasionally, he contributes to the “Points of View” data visualization column in Nature Methods. Gehlenborg currently serves as the Director of the Master of Biomedical Informatics (MBI) program at Harvard Medical School.
|Nicholas George, PhD||Streck|
Research & Development Scientific Manager, Research and Development
Nicholas (Nick) George received his PhD in Cancer Biology from the University Nebraska Medical Center, then joined Streck Inc. in 2015. His current research and development interests include liquid biopsy and the multitude of pre-analytical variables associated with sample collection, processing, and analysis.
|Jason Gerhold||Invivoscribe, Inc.|
Global Director, Regulatory Affairs and Quality Assurance
Jason Gerhold, Invivoscribe’s Global Director of RA & QA, has 20 years of experience in the biotechnology industry, 15 of which while in regulatory affairs, quality, and clinical affairs positions. He joined Invivoscribe in 2012 to lead companion diagnostic regulatory development strategies resulting in international CDx approvals supporting multiple drugs. He was integral in implementing quality systems and obtaining regulatory approvals while with Millipore (Light Diagnostics) and Shire Regenerative Medicine.
|Maryam Gholami||Providence Health & Svcs|
Vice President, Chief Product Officer, Digital Innovations
Maryam Gholami is vice president, head of product, design and development for digital innovations at Providence St. Joseph Health (PSJH). She brings over 15 years of experience in building technology products and companies, leading multidisciplinary teams including product, design, and engineering, within well-established companies and start-ups such as Microsoft, Practice Fusion and Zoi Health. At PSJH, she is responsible for the incubation and growth of the consumer digital products portfolio and also applications of advanced technologies such as AI and machine learning to bring access and convenience to consumers, simplify caregiving and increase operational efficiency. With almost 10 years of experience in machine learning and artificial intelligence including information retrieval, recommendation engines, NLP, voice, and computer vision, Maryam has been instrumental in moving healthcare forward with AI. Some of her most recent work includes AI-enabled HIPAA compliant voice skills through partnership with Amazon Alexa, digital health assistant chatbot for navigation and triage, and applications of computer vision in digital payment and registration. Prior to PSJH, Maryam was the co-founder and CEO of Zoi Health, a start-up which combined the power of human coaches and AI to provide ongoing monitoring and health coaching to people with chronic conditions such as Diabetes and Hypertension.
|Mark Girardi||Boston Healthcare|
Senior Vice President
Mark Girardi has over 30 years of experience in life sciences, in vitro diagnostics, and medical devices commercialization and reimbursement. He has had roles in product management, sales and marketing, and most recently in strategy consulting. Mr. Girardi joins us from GfK Health, a global consultancy and market research firm, where he was Senior Vice President responsible for the MedTech consulting practice.
|Harry Glorikian, MBA||New Ventures Funds|
Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends. He holds four US patents in telecommunications, and has others pending. He recently served as an Entrepreneur In Residence to GE Ventures – New Business Creation Group. He serves on the board of GeneNews Ltd. (a molecular diagnostic company). He also serves on the advisory board of Nucelis (a gene-editing industrial biotech company), Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board member of DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Ventures). Previously he co-founded and held the position of managing director and head of consulting services for Scientia Advisors, a company that became the go-to provider of strategic advice and implementation services for next-generation healthcare and life science innovators and Global 25 market leaders. Scientia Advisors was acquired by Precision for Medicine in November of 2012. Among his other professional roles, Mr. Glorikian served as senior manager for global business development at PE Applied Biosystems, founded X-Cell Laboratories, managed global sales at Signet Laboratories and held various roles at BioGenex Laboratories. Mr. Glorikian holds an MBA from Boston University and a bachelor's degree from San Francisco State University. Harry has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many other media outlets.
|Bert Gold, PhD, FACMG||Gold Standard Genetics LLC|
Dr. Bert Gold is principal consultant at Gold Standard Genetics LLC, a firm he founded in March 2018 after 28 years of experience in genetics and genomics. Through this time, Dr. Gold has been evaluating, testing, mapping, developing, implementing and commercializing human molecular genetic diagnostics. Gold Standard Genetics LLC has provided laboratory compliance consulting services to a major pharmaceutical corporation and a K Street law firm partner, marketing consulting to major European and American diagnostics manufacturers, large references laboratories, and strategic advice to cancer diagnostics and perinatal diagnostics start-ups. Dr. Gold has held molecular genetics laboratory positions at UMDNJ, Temple, Jefferson Medical College, UCSF, SmithKline/Quest, NIH/NCI, Natera, Novogene and BillionToOne. He is board-certified in Clinical Molecular Genetics, a Fellow of the American College of Medical Genetics and is a licensed laboratory director in all 50 states. He is currently collaborating on standards for the Clinical Laboratory Standards Institute on Liquid Biopsy in Cancer and Non-invasive prenatal testing.
|Tanya Gottlieb, PhD||MeMed|
Vice President, Scientific Affairs
MeMed’s VP Scientific Affairs, Tanya cultivates strategic alliances with public and third sectors. She has extensive academia and biotech experience, specializing in international collaborations and non-dilutive financing. Before MeMed, Tanya was BD Director at BiondVax, a universal flu vaccine developer. Tanya conducted postdoc research at Weizmann Institute, Israel and Fred Hutchinson Cancer Research Center, USA and holds a BA in Natural Sciences and PhD from Cambridge University, UK and an MBA from the Technion, Israel.
|Chris Gough||Intel Corp|
General Manager, Health & Life Sciences
Chris Gough is Worldwide General Manager of Health and Life Sciences at Intel Corporation. In this role, Chris leads a team of technology leaders and subject matter experts to develop solutions that use information and communication technology to transform the health and life sciences industry. He works with companies, organizations and governments around the world to help make this digital transformation a reality. With over 15 years of industry experience, Chris brings deep healthcare and life sciences expertise along with a foundation in technology and its application to multiple industries. He has been with Intel for over 20 years and was formerly both product and security architect in Intel’s Digital Health division. In this role, he was the chief architect for several products including, Care Connect, and Integration Services for the Intel Health Guide. Mr. Gough has been an active member of the Continua Health Alliance and was one of the lead contributors to the end-to-end system architecture and interoperability guidelines. He holds a Bachelor of Science in computer science from the University of California at San Diego..
|Naside Gozde Durmus, PhD||Stanford Univ|
Assistant Professor, Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine
Gozde Durmus is a postdoctoral research fellow at Stanford University working with Prof. Ronald W. Davis and Prof. Lars Steinmetz at the Stanford Genome Technology Center. She received her PhD degree in Biomedical Engineering from Brown University in May 2013, with a minor in Innovation Management and Entrepreneurship. She is also an alumna of the Ignite Program at the Stanford University Graduate School of Business. She was a Fulbright Scholar at Boston University and received her MEng degree in Biomedical Engineering as a College of Engineering Fellow in 2009. She received her BS degree in Molecular Biology and Genetics from Middle East Technical University (METU) in 2007. She has been recently recognized among the "Top Innovators Under 35" (TR35) by the MIT Technology Review.
|Ralph Graeser, PhD||Boehringer Ingelheim Pharma GmbH & Co KG|
Senior Translational Medicine Expert
Ralph received his PhD in Biochemistry at the University of Basel for his thesis on malarial CDK-like kinases. He continued to work on CDK-like kinases as a postdoc at the Imperial Cancer Research Fund (ICRF) in the lab of Nobel laureate Prof. Tim Hunt. Still following his interest in protein kinases, he then joined ProQinase GmbH to support drug discovery and translational fee-for-service projects in Oncology. Applying his experience in oncology drug discovery/early development, he subsequently moved to Janssen and later Böhringer Ingelheim to support the translation of Oncology programs from Research to the clinic. In addition to working on biomarker strategies, he has been involved in several IMI-projects, including the PREDECT program, for which he acted as a co-coordinator, and CANCER-ID.
|Hank Greely, JD||Stanford Univ|
Professor by courtesy of Genetics, Stanford School of Medicine; Director, Center for Law and the Biosciences; Director, Stanford Program in Neuroscience and Society; and Chair, Steering Committee of the Center for Biomedical Ethics
Henry T. (Hank) Greely is the Deane F. and Kate Edelman Johnson Professor of Law and Professor, by courtesy, of Genetics at Stanford University. He specializes in ethical, legal, and social issues arising from advances in the biosciences, particularly from genetics, neuroscience, and human stem cell research. He is President of the International Neuroethics Society; directs the Stanford Center for Law and the Biosciences and the Stanford Program on Neuroscience in Society; chairs the California Advisory Committee on Human Stem Cell Research; and serves on the Committee on Science, Technology, and Law of the National Academy of Sciences; the National Academies’ Committee on Developing a Research Agenda and Research Governance Approaches for Climate Intervention Strategies that Reflect Sunlight to Cool Earth; and the NIH BRAIN Initiative’s Multi-Council Working Group, whose Neuroethics Division he co-chairs. He published THE END OF SEX AND THE FUTURE OF HUMAN REPRODUCTION in May 2016. Professor Greely graduated from Stanford in 1974 and from Yale Law School in 1977. He served as a law clerk for Judge John Minor Wisdom on the United States Court of Appeals for the Fifth Circuit and for Justice Potter Stewart of the United States Supreme Court. After working during the Carter Administration in the Departments of Defense and Energy, he entered private law practice in Los Angeles in 1981. He joined the Stanford faculty in 1985.
|George Green, PhD||Bristol Myers Squibb Co|
Executive Director, Head Pharmacodiagnostics
George A. Green, IV PhD is Head, Pharmacodiagnostics in the Bristol-Myers Squibb Translational Medicine organization. He joined BMS in March 2010 and played a key role in establishing Pharmacodiagnostics as a core capability within BMS. In his role, George has been responsible for leading pharmacodiagnostic development programs in oncology, neuroscience, cardiovascular, and virology, as well as early diagnostic development programs in a number of therapeutic areas and across multiple technology platforms. In his current role, George heads the Pharmacodiagnostics team, providing strategic direction and support for all diagnostic platforms across the portfolio BMS Oncology and Innovative Medicine assets.
|David Greenberg, MD||University of Texas Southwestern|
Associate Professor, Microbiology and Internal Medicine
Dr. Greenberg is a physician-scientist who completed his Infectious Diseases training at the National Institutes of Health. He was recruited to UT Southwestern in 2010. He is currently an Associate Professor and Distinguished Teaching Professor as well as the Director of Microbial Genomics in the Division of Infectious Diseases. Dr. Greenberg’s research focuses on antimicrobial resistance both from the therapeutic as well as the diagnostic domains. His therapeutic work involves the development of pathogen-specific antimicrobials utilizing an antisense approach. In addition, David is involved in developing new tools to predict antibiotic resistance from next-generation sequencing data. This includes using machine learning approaches to predict antibiotic resistance without the need for phenotypic testing.
|Casey Greene||Univ of Pennsylvania|
|Nabil Hafez, MS||Sunquest Information Systems|
Senior Director, Product Management Precision Medicine
Nabil brings extensive experience to Sunquest. Prior, he was Product Director, Neurology, Quest Diagnostics; Director, Clinical Strategy, GenomeQuest; Founder, SeqWise, an NGS consultancy; and began his career at Broad Institute. Nabil holds an MBA from Duke, an MS in Bioinformatics from Brandeis, and a BS in Biology from Binghamton.
|Hisham Hamadeh, PhD, MBA||Genmab US Inc|
Vice President, Global Head, Data Science
No bio available
|Sam Hanash, MD, PhD||MD Anderson Cancer Ctr|
Director, McCombs Institute for Cancer Detection and Treatment
Dr Hanash was recruited to MD Anderson Cancer Center in 2011 to lead the Red and Charline McCombs Institute for Cancer Early Detection and Treatment. He was previously program head for Molecular Diagnosis at the Fred Hutchinson Cancer Research Center. Dr. Hanash’s interest and expertise are in the field of cancer diagnostics and the development of blood-based cancer biomarkers for risk assessment and cancer early detection. He is the inaugural president of the International Human Proteome Organization dedicated to the study of the human proteome, and a founder of the US Human Proteome Organization. Dr Hanash’s approaches to meet the challenge of developing markers that signal the presence of cancer at an early stage to allow detection and effective treatment have included a rigorous painstaking in-depth quantitative profiling of the various types of molecules in the blood to find those that are released early either from the cancer cells or from the host response to the developing cancer. The work emphasizes the need for rigor in experimental design, in data collection and statistical analysis and in developing a mechanistic understanding of the relationship between the identified cancer markers and the developing cancer. This work has sparked innovation in experimental design and statistical analysis of biomarker data aimed at minimizing biases in discovery studies through prospective sample collections that relate most directly to the intended clinical application(s) and at reducing the false discovery rate through integration of data from multiple sources to increase confidence in the significance of the markers.
|Stefan Harrer, PhD||IBM; University of Technology Sydney|
Manager and Research Staff Member, Brain-Inspired Computing, IBM Research; Adjunct Professor, School of Engineering and Information Science, University of Technology Sydney
In 2015 Stefan founded the Brain-Inspired Computing Research program of IBM Research – Australia and now leads it as its Manager. His team spearheads an effort to develop AI-based technology for managing and treating epilepsy. Since joining IBM Research in 2008, Stefan has worked in the fields of biotechnology, nanotechnology and healthcare analytics at IBM Albany Nanotech, and the IBM T.J. Watson Research Center in New York as well as at IBM Research Australia. He has authored and co-authored over 40 technical publications and holds over 50 issued and over 60 pending patents. Stefan has been named IBM Master Inventor in 2017 and was elected into the IBM Academy of Technology in 2018. He holds an Adjunct Professor position in the School of Engineering and Information Science at the University of Technology Sydney. As a Member of the New York Academy of Sciences and Senior Member of the IEEE he is part of the IEEE Computer Society Steering Committee and an Associate Editor of the IEEE Transactions on Nanobioscience. Stefan has received a Research Scholarship from UC Berkeley, a Karl Chang Innovation Fund Grant from MIT, an Honorary Principal Research Fellowship from the University of Melbourne and several Research Grants from the NIH and the Australian Research Council. His work has been featured in WIRED Magazine, The World Economic Forum, ABC News, IEEE Spectrum, The Australian Academy of Science, Popular Science and R&D Magazine among others. He holds a PhD in EECS from the Technical University Munich and an Honours Master’s Degree in Technology Management from the Center for Digital Technology and Management.
|Anne-Renee Hartman, MD||Biotech Executive, Advisor, and Investor|
Biotech Executive, Advisor, and Investor
Anne-Renee Hartman is the former acting CMO and VP of Clinical Development and Medical Affairs at GRAIL where she was responsible for the design and execution of clinical programs to discover and validate cell-free nucleic acid technology for early detection of cancer. Prior to GRAIL, Anne-Renee was the Senior Vice President of Clinical Development at Myriad Genetics, Inc. At Myriad, Anne-Renee led the development of several commercialized diagnostics in oncology, including hereditary cancer testing, companion diagnostics for PARP therapy, and diagnostic and prognostic assays for melanoma, lung, and prostate cancer. Anne-Renee was previously an Assistant Professor of Medicine at The Dana-Farber Cancer Institute, specializing in breast cancer genetics. She completed her oncology fellowship at Stanford where she helped set up the cancer genetics clinic. Anne-Renee holds a BS in Molecular Biology from Princeton University, an MD from the University of Michigan, and completed her residency in Internal Medicine at the University of Chicago.
|Christopher Hartshorn, PhD||NIH NCI|
Program Director, Division of Cancer Treatment and Diagnosis
Dr. Christopher M. Hartshorn serves as a program director at the National Cancer Institute (NCI) of the National Institutes of Health. In this role, he manages nano- and passive continuous monitoring-centric research projects, evaluates effectiveness of the programs, and maintains proper stewardship over federally funded research. Furthermore, he serves as a technical expert to extramural programs and participates in development and direction of new research initiatives within the NCI Division of Cancer Treatment and Diagnosis. Prior to the NCI, Dr. Hartshorn worked for the National Institute of Standards and Technology (NIST).
|Paul Hastings||Nkarta Inc|
President and CEO
Paul Hastings was appointed Chief Executive Officer of Nkarta in February 2018. Mr. Hastings was recently the Chairman and CEO of OncoMed Pharmaceuticals. Prior to joining OncoMed in 2006, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President, Genzyme Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche.
He is currently Lead Independent Director of Pacira Biosciences, Inc., Chairman of the Board at Proteon Therapeutics, and Director at ViaCyte. He also serves as Vice Chair and member of the Executive Committee of the Biotechnology Innovation Organization (BIO). Mr. Hastings was recently on the Board of Directors of Relypsa, Inc. (acquired by Galenica), was Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2010) and served on the board of ViaCell (sold to Perkin-Elmer in 2007).
Mr. Hastings received a Bachelor of Science degree in pharmacy from the University of Rhode Island.
|Lucy Hattingh||Lucy Hattingh Consulting|
Lucy has been consulting to IVD test manufacturers since 2015 supporting more than 20 companies and providing a deep understanding of the road to market for IVD tests from product concept to launch. She also works for various organizations in the global public health sector where the emphasis is on building access to diagnostics in low- and middle-income countries (LMICs). She has 30 years of experience commercializing products in the Life Science Research and Diagnostics industries, with much of that time in molecular diagnostics. She managed sales and marketing teams for Roche Molecular Diagnostics in South Africa and Canada and has led marketing teams with global responsibility for various companies including Roche Molecular Diagnostics and Gen-Probe (now Hologic) for more than 10 years. She holds a Bachelor of Science Honours degree in Medical Biochemistry from the University of Cape Town Medical School, and an MBA from IMD in Switzerland.
|David Haussler, PhD||Univ of California Santa Cruz|
Distinguished Professor and Scientific Director, UC Santa Cruz Genomics Institute
David Haussler develops new statistical and algorithmic methods to explore the molecular function, evolution, and disease process in the human genome, integrating comparative and high-throughput genomics data to study gene structure, function, and regulation. He is credited with pioneering the use in genomics of hidden Markov models (HMMs), stochastic context-free grammars, and discriminative kernel methods. As a collaborator on the international Human Genome Project, his team posted the first publicly available computational assembly of the human genome sequence on the Internet on July 7, 2000. His team subsequently developed the UCSC Genome Browser, a web-based tool that is used extensively in biomedical research and serves, along with the Ensembl platform, virtually all large-scale vertebrate genomics projects, including NHGRI’s ENCODE project, the 1000 Genomes Project, and NCI’s TCGA. He built the CGHub database to hold NCI’s cancer genome data and is a co-founder and organizing member of the Global Alliance for Genomics and Health (GA4GH), a coalition of the top research, health care, and disease advocacy organizations that have taken the first steps to standardize and enable secure sharing of genomic and clinical data. Haussler received his PhD in Computer Science from the University of Colorado, Boulder. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences and a fellow of AAAS and AAAI. He has won a number of awards, including the 2014 Dan David Prize, in the Future category, 2011 Weldon Memorial prize for application of mathematics and statistics to biology, 2009 ASHG Curt Stern Award in Human Genetics, the 2008 Senior Scientist Accomplishment Award from the International Society for Computational Biology, the 2006 Dickson Prize for Science from Carnegie Mellon University, and the 2003 ACM/ AAAI Allen Newell Award in Artificial Intelligence.
|Hunter Hill, PharmD||Kroger Health|
Pharmacy Manager, Delta Division
Dr. Hunter Hill, PharmD is a Pharmacy Manager for the Delta Division of Kroger Health located in Memphis, TN. Dr. Hill is a recent graduate of the University of Tennessee PGY1 Community-Based Residency Program after completing his PharmD from the University of Tennessee Health Science Center. During his residency year, Dr. Hill implemented a pilot-program in which pharmacy technicians were trained to support pharmacists with the technical aspects, including sample collection, of point-of-care testing. This falls into his current interests of leveraging pharmacists to provide high-quality patient care. The results of his research were presented in poster format at the American Pharmacists Association (APhA) Annual Meeting & Exposition and a podium presentation at the Research in Education & Practice Symposium. Dr. Hill In addition to his research interests, he also serves as a preceptor for both the UTHSC PGY1 Community-Based Residency Program and Advanced Pharmacy Practice Experience (APPE) students for the College of Pharmacy. He has also served as a guest lecturer for several courses within the College of Pharmacy.
|Kenneth Hohmeier, PharmD||University of Tennessee Health Science Center|
Associate Professor, Director of Community Affairs, Clinical Pharmacy & Translational Science
Dr. Kenneth Hohmeier, PharmD is Associate Professor of Clinical Pharmacy & Translational Science at the University of Tennessee Health Science Center (UTHSC) in Nashville, TN. Dr. Hohmeier engages in a variety of community pharmacy scholarship, mainly in the fields of effectiveness and implementation science research. His currently funded research projects include investigating a new model of medication therapy management (MTM) delivery and implementation for Tennessee’s Medicaid population, point-of-care testing (POCT) implementation and consumer perceptions, use of pharmacist-extenders to improve pharmacy care quality and delivery, and interventions and implementation strategies to reduce vaccine hesitancy. In addition to his research interests, he maintains an active practice site at a community pharmacy in Nashville, TN. He also serves as Residency Program Director (RPD) for the UTHSC PGY1 community-based residency program, is Director of Community Affairs for the College of Pharmacy, and serves as a course director and lecturer for several courses within the College of Pharmacy.
|Kyle Holen, MD||AbbVie Inc|
Head, Development Design Center
A leader in the field of advanced analytics and data, Kyle helped create, and now heads, AbbVie’s Development Design Center where he works with teams all over the world to ensure innovation, health technologies, and data tools are incorporated into AbbVie’s clinical trials. Whether it’s using real-world evidence and machine learning or incorporating wearables, sensors, and other devices into clinical trials, Kyle’s goal is to bring new and better treatments to more patients, faster. Before coming to AbbVie, Kyle was a physician who treated cancer patients and saw first-hand patients battle some of the most devastating diseases.
|Mark Hulse||City of Hope Natl Medical Ctr|
Chief Digital Officer
Mark Hulse is the Chief Digital Officer for City of Hope where he serves as a key member of the Executive Leadership Team and is responsible for fostering a transformative digital culture and leading digital solution development across City of Hope. In this role, Hulse is charged with solving key business challenges and leads a broad range of digital initiatives to support City of Hope's clinical, research, operations and administrative objectives.
Prior to this, Hulse served as CEO of the THEO Executive Group, which provides leadership advisory services to healthcare enterprises nationally. Hulse also served as the Chief Administrative Officer at the Moffitt Cancer Center and, prior to that, was the Chief Information Officer at Moffitt.
Prior to joining Moffitt, he was the VP and CIO for North Shore Medical Center, part of the Partners Healthcare System in Boston, Massachusetts. His health care background also includes 11 years at Massachusetts General Hospital in Boston and 8 years with Stanford University Medical Center in California.
|Hilja Ibert, PhD||Gentian USA Inc|
Gentian’s CEO Dr. Hilja Ibert’s vision is to innovate diagnostic efficiency together with her inter-disciplinary and international team at Gentian. She is a hands-on CEO, driving development and commercialisation of product solutions for the clinical diagnostics market. Dr. Hilja Ibert has over 25 years’ experience from the international diagnostic industry, from which she has proved her extensive leadership skills. She has previously held the position as VP International Diagnostic Solutions at Hologic, and several senior positions within Becton Dickinson and bioMerieux. Dr. Hilja Ibert also has experience with early stage R&D companies, like her position as CEO for miDiagnostics in Belgium. Dr. Hilja Ibert holds a PhD degree in Nutrition Science from the University of Bonn, Germany.
|David Issadore, PhD||Univ Of Pennsylvania|
Assistant Professor, Bioengineering & Electrical & Systems Engineering
David Issadore's research focus is on microelectronics, microfluidics, nanomaterials and molecular targeting, and their application to medicine. These multidisciplinary skills enable him to explore new technologies that can bring medical diagnostics from expensive, centralized facilities, directly to clinical and resource-limited settings. He has developed hybrid chip designs, a portable NMR system and the micro Hall detector.
|Elena Izmailova, PhD||Koneksa Health Inc|
Dr. Elena Izmailova is a clinical scientist with a unique background bridging technology innovation, scientific strategy, and business management. Her main interests lie in biomarker discovery, development, and utilization in the context of clinical trials. Elena is currently Chief Scientific Officer of Koneksa Health, an innovative technology company that accelerates development of new medicines by leveraging wearable technologies to collect real world data, enabling the biopharmaceutical industry to execute more efficient and successful clinical trials. Prior to her appointment with Koneksa Health, Elena led the wearable device clinical innovation group at Takeda Pharmaceuticals, where she created a comprehensive digital roadmap for technology-enabled clinical development. Elena joined the pharmaceutical industry in 2003. At Millennium Pharmaceuticals she led cross-functional teams to develop and deploy clinical biomarker strategies and directed the bio-analysis function responsible for biomarker assay development, validation and implementation across multiple therapeutic areas and in global clinical trials. She additionally established fruitful collaborations with investigators at several major teaching hospitals, leading to discovery and characterization novel disease biomarkers, and resulting in multiple publications and conference presentations. Elena holds PhD in Biology. She completed postdoctoral training at Massey Cancer Center/MCV and at Children’s Hospital/Harvard Medical School. She has also held a visiting scientist position at the Whitehead Institute of MIT.
|Howard Jacob, PhD||AbbVie Inc|
Vice President and Head, Genomic Research, Drug Discovery Science & Technology, Distinguished Research Fellow
Howard J. Jacob, PhD, was a member of the first team ever to use genome sequencing to diagnose, treat and cure a patient. It was 2009, and the patient was a 6-year-old whose symptoms baffled doctors for years. Working with scientists and physicians, Dr. Jacob’s team sequenced the boy’s DNA and diagnosed his rare disease, which allowed him to undergo a successful bone marrow transplant.
Almost a decade later, Dr. Jacob is using the same technology to potentially help millions of patients. As AbbVie’s new vice president and head of genomic research, he brings decades of genomic knowledge from academia and the clinic into the company’s labs. We spoke with Dr. Jacob about the current state of whole genome sequencing, and its potential for both patients and those simply interested in learning more about their “own personal blueprint.”
Chief Commercial Officer & President
Olivier Jarry is President and Chief Commercial Officer of DarioHealth (www.dariohealth.com, Nasdaq: DRIO), a digital therapeutics company supporting people with diabetes and other chronic conditions with digitally-based, clinically-proven interventions. He has launched new products (digital and physical products) and new business models for fast-growing companies and large pharma such as Novartis, Bayer Diabetes Care or BMS, around the world. Olivier holds a TRIUM executive MBA (NYU Stern, LSE London, HEC Paris), a MEng from the French DOD and a MSc from Ecole Centrale de Paris.
|Mehdi Javanmard, PhD||Rutgers University New Brunswick|
Associate Professor, Electrical and Computer Engineering
Mehdi Javanmard joined Electrical and Computer Engineering Department at Rutgers University in Fall 2014 as Assistant Professor. Before that he was Senior Research Engineer at the Stanford Genome Technology Center (SGTC) in the School of Medicine at Stanford University. He received his BS (2002) from Georgia Institute of Technology and the MS in Electrical Engineering at Stanford University (2004). In 2008, he received his PhD in Electrical Engineering at Stanford University working on development of electronic microfluidic platforms for low cost genomic and proteomic biomarker detection. At SGTC, he worked as a postdoctoral scholar from 2008-2009, and then as a staff engineering research associate from 2009 till 2014. In 2017 he was recipient of the Translational Medicine and Therapeutics Award by the American Society for Clinical Pharmacology & Therapeutics for his group's work in point of care diagnostic tools for assessing patient response to cancer therapies. He received the National Science Foundation CAREER Award in 2019. He has received various awards as Principal Investigator from the National Science Foundation, DARPA, and the PhRMA foundation to support his research. His interests lie in developing portable and wearable technologies for continuous health monitoring and understanding the effects of environment on health.
|Stefanie Jeffrey, MD||Stanford Univ|
John and Marva Warnock Professor, Surgery; Chief, Surgical Oncology Research, Stanford University School of Medicine
Stefanie Jeffrey, MD, is the John and Marva Warnock Professor and Chief of Surgical Oncology Research in the Department of Surgery at Stanford University School of Medicine. She received her undergraduate degree in Chemistry and Physics and master’s degree in Chemistry from Harvard University. She graduated from medical school at University of California San Francisco (UCSF), where she also completed her surgical residency. Her lab focuses on technology development and applications related to liquid biopsy (CTCs, ctDNA, extracellular vesicles), droplet-based microfluidic platforms, and preclinical models for testing new cancer therapies.
|Jin Jen, MD, PhD||Mayo Clinic & Foundation|
Professor, Laboratory Medicine and Pathology
The primary research focus of Jin Jen, MD, PhD, is the molecular genetics of non-small cell lung cancer. Dr. Jen is an expert in next-generation sequencing (NGS)-based technologies and in using this platform to identify tumor-associated molecular alterations for cancer detection, prognosis and treatment stratification. Dr. Jen is co-director of the Genome Analysis Core of the Medical Genome Facility within the Center for Individualized Medicine (CIM) at Mayo Clinic. In this capacity, she leads the technology development operations and has enabled the optimization and implementation of NGS-based technologies for whole-transcriptome sequencing using a variety of sample types for research and clinical applications. Dr. Jen is also member of the Biomarker Discovery Program in CIM. She collaborates closely with both basic and clinical scientists using state-of-the-art technologies for biomarker and bioassay discoveries and test development to improve the ability to assess lung cancer progression, treatment response and outcome.
|Claus Jensen, PhD||Memorial Sloan Kettering Cancer Ctr|
Chief Digital Officer & Head of Technology
Claus is the Chief Technology Officer for CVS Health, leading Technology Innovation, Business Transformation Incubation, Architecture Planning, Delivery and Forensics, Digital Integration and M&A activities across CVS Health. Plays a pivotal role in becoming a trusted health partner delivering a connected experience. Claus has been with CVS Health/Aetna since February 2015. His prior background spans 20 years of transformational leadership roles at Danske Bank and IBM. During his time at IBM he was a trusted advisor on business and IT transformation journeys for many of the Fortune 100 companies. Claus has a PhD in Computer Science from Aarhus University, Denmark. He is a thought leader in business and IT integration, holds 14 patents, and is a published author of five books and numerous articles.
|Shidong Jia||Predicine Inc.|
Founder & CEO
Shidong Jia, MD, PhD, is the Founder and CEO of Predicine. Prior to founding Predicine, Shidong spearheaded the oncology biomarker strategies and drug & diagnostics co-development at Genentech. He previously held various research positions focusing on translational and clinical cancer research at Novartis Institutes for BioMedical Research and Harvard University.
|Zhaoshi Jiang, PhD||Gilead Sciences Inc|
Executive Director of Bioinformatics & Clinical Data Sciences
Over two decades of translational research experience in both clinical, academic and industrial settings, focus on genomics, clinical data sciences in the area of infectious disease, oncology, and inflammatory disease. Excellent understanding of current trends and technologies in bioinformatics and big data to support translational research. Extensive leadership experience in a cross-functional environment in pharmaceutical companies. Strong management experience in hiring, building and supervising a bioinformatics & clinical data sciences team.
|Joen Johansen||MDC Associates Inc|
Joen is President of MDC Associates, Inc. a full-service RA/QA/CRO servicing diagnostic companies. Joen has more than 17 years of marketing, sales, business development and management experience in the IVD industry. Prior to MDC he was Head of Global Marketing for Accelerate Diagnostics, Inc. where he was responsible for the global launch of the Accelerate Pheno™ system. The system is the first rapid AST platform and was approved for use in the US via the FDA de novo process. Joen has helped to define, develop and commercially launch more than 16 FDA-cleared, CE-marked IVD products in the United States and Europe. Prior to joining the IVD industry Joen was a Healthcare Investment Banker with Lehman Brothers in London. Joen has degrees in Molecular Biology & Biochemistry and Economics from Wesleyan University.
|Kirsten Johnson, PhD||InSilxa|
Research and Development Senior Manager
No bio available
|Alexandre Juillerat, PhD||Cellectis Inc|
US Laboratory Head and Team Leader
Dr. Alexandre Juillerat, PhD, graduated in Chemistry from the University of Lausanne, Switzerland. After receiving his PhD in 2006 in protein engineering from the École Polytechnique Fédérale de Lausanne (EPFL, Switzerland), he moved to the laboratory of Structural Immunology at the Institut Pasteur in Paris, France. In 2010, he joined the R&D department of Cellectis in Paris, France, working on the development and implementation of sequence specific designer nucleases including the transcription activator-like effector nucleases (TALEN®). He then joined the Cellectis facility based in New York, NY, USA, leading projects associated with the development of the T-cell chimeric antigen receptor (CAR) technology.
|Daniel Karlin, MD||HealthMode|
Dr. Karlin is the CEO at HealthMode.co, and Chief Medical Officer at NightWare. He was previously the Head of Clinical, Informatics, and Regulatory Strategy for Digital Medicine at Pfizer, having passed through a number of roles on the way to this position including Senior Director, Quantitative Medicine, Group Lead for Human Biology and Medical Informatics with Pfizer’s Neuroscience Research Unit in Cambridge, MA. He is an Assistant Professor at Tufts Medical Center in Boston, and had been the Director of Psychiatry Informatics, and the Associate Training Director for Psychiatry. His primary research interests are neuropsychiatric drug development, medical informatics, cognition in clinical medicine, and methods for medical education, especially as these relate to decision-making strategies used by medical professionals. In addition, Dr Karlin is actively involved in designing and implementing information systems and resources for clinical and research use. Dr Karlin trained in Psychiatry at Tufts Medical Center, attended medical school at the University of Colorado School of Medicine, and graduate school for Clinical Informatics and Cognitive Science as well as undergraduate studies in Neuroscience and Behavior at Columbia University. He is board certified in Psychiatry, Addiction Medicine, and Clinical Informatics.
|Adam Kaufman, PhD||Canary Health Inc|
President & CEO
As an engineer and data scientist, Adam’s passions include improving lives through implementing new technologies and rigorous analysis of impact. Prior to co-founding Canary Health, Adam was GM of Healthcare Services at dLife. He received his PhD in Health Economics from USC where he taught econometrics and health economics. He is also Board Chair of Mental Health America, Los Angeles
|Mustaqhusain Kazi||Genentech Inc|
Head of Personalized Healthcare, Pharma Informatics
No bio available
|Allison Keeler-Klunk, PhD||Univ Of Massachusetts|
Assistant Professor, Pediatrics, University of Massachusetts Medical School
Dr. Keeler-Klunk holds a PhD in Biomedical Sciences from the University of Massachusetts Medical School from the laboratory of Terence Flotte studying on AAV gene therapy for fatty acid oxidation. She went on to complete three postdoctoral fellowships focusing on AAV gene therapy for neurological, neuromuscular and respiratory diseases. The main focus of her lab is focused on modulating immune responses to AAV gene therapy, and genome editing of immune and stem cells for different therapeutic applications.
|Shana Kelley, PhD||Univ of Toronto|
Professor, Department of Biochemistry, Leslie Dan Faculty of Pharmacy
Dr. Shana Kelley is a Distinguished Professor of Chemistry, Pharmaceutical Sciences, Biochemistry, and Biomedical Engineering at the University of Toronto. Dr. Kelley received her PhD from the California Institute of Technology and was a NIH postdoctoral fellow at the Scripps Research Institute. The Kelley research group works in a variety of areas spanning biophysical/bioanalytical chemistry, chemical biology and nanotechnology, and have pioneered new methods for tracking molecular and cellular analytes with unprecedented sensitivity. Dr. Kelley’s work has been recognized with a variety of distinctions, including being named one of “Canada’s Top 40 under 40”, a NSERC E.W.R. Steacie Fellow, the 2011 Steacie Prize, and the 2016 NSERC Brockhouse Prize. She has also been recognized with the ACS Inorganic Nanoscience Award, Pittsburgh Conference Achievement Award, an Alfred P. Sloan Research Fellowship, a Camille Dreyfus Teacher-Scholar award, a NSF CAREER Award, a Dreyfus New Faculty Award, and was also named a “Top 100 Innovator” by MIT’s Technology Review. Shana is a founder of two molecular diagnostics companies, GeneOhm Sciences (acquired by Becton Dickinson in 2005) and Xagenic Inc. (acquired by General Atomics in 2017), and sits on the Board of Directors of the Ontario Genomics Institute and the Fight Against Cancer Trust. She is an Associate Editor for ACS Sensors, and an Editorial Advisory Board Member for the Journal of the American Chemical Society and ACS Chemical Biology.
|Shameer Khader, PhD||AstraZeneca Pharmaceuticals Inc|
Senior Director, Advanced Analytics, Data Science and Bioinformatics
No bio available
|Faisal Khan, PhD||AstraZeneca Pharmaceuticals Inc|
Executive Director, Advanced Analytics and AI
Researcher in the applications of computational and statistical learning and analytical techniques for biomedical and other problems. Particularly in developing CLIA/LDT/IVD personalized molecular diagnostic assays, wearable devices and in drug development. Experienced in leading scientists and technical experts, and in representing technical issues and competencies to executive management and investors.
|Lukasz Kidzinski, PhD||Stanford University|
Łukasz Kidziński is a researcher in the Mobilize Center at Stanford, working on the intersection of computer science, statistics, and biomechanics. Previously a researcher in the CHILI group, Computer-Human Interaction in Learning and Instruction, at the EPFL. He obtain his PhD training at Université Libre de Bruxelles in mathematical statistics, working on time series analysis and functional data. He obtained two master degrees, in mathematics and in computer science, from the University of Warsaw.His research interest include machine learning, data mining, big data, time series analysis and applied statistics. His main area of applications are biomedical data science, biomechanics and computer-human interactions.
|Stephen Kingsmore, MD, DSc||Rady Childrens Hospital San Diego|
President/CEO, Rady Children’s Institute for Genomic Medicine
Dr. Stephen Kingsmore is President and CEO of Rady Children’s Institute for Genomic Medicine, where he leads a multi-disciplinary team of scientists, physicians and researchers who are pioneering the use of rapid Whole Genome Sequencing (WGS) to diagnose and guide precision medical care for critically-ill newborns. An expert in genomic and systems medicine research, Dr. Kingsmore holds the world speed record for achieving the fastest molecular diagnosis using whole genome sequencing in 19.5 hours. Following a nationwide search, he was selected as the founding President and CEO of the Rady Children’s Institute for Genomic Medicine (RCIGM) in September 2015. The mission of the Institute is identifying the genetic cause of rare diseases in acutely ill newborns and children through rapid and ultra-rapid WGS. Dr. Kingsmore came to Rady Children’s from Children’s Mercy Kansas City, where he was the Founding Director of the Center for Pediatric Genomic Medicine. He also held the Dee Lyons/Missouri Endowed Chair in Genomic Medicine at the University of Missouri-Kansas City School of Medicine. In his distinguished career, Dr. Kingsmore has also served as President and CEO of the National Center for Genome Resources; COO of Molecular Staging Inc.; Vice President of Research at CuraGen Corporation; founder of GatorGen; and Assistant Professor at the University of Florida’s School of Medicine. Dr. Kingsmore received MB ChB BAO and DSc degrees from the Queen’s University of Belfast. He trained in clinical immunology in Northern Ireland and did residency in internal medicine and fellowship at Duke University Medical Center. He is a fellow of the Royal College of Pathologists. He received the 2013 Scripps Genomic Medicine award for pioneering discoveries in neonatal care and TIME magazine ranked his rapid genome diagnosis method one of the top 10 medical breakthroughs of 2012.
|Jeffrey Klausner, MD, MPH||University of California, Los Angeles|
Professor of Medicine and Public Health, David Geffen School of Medicine
Jeffrey Klausner, MD, MPH, is a Professor of Medicine in the Division of Infectious Diseases in the David Geffen School of Medicine and Adjunct Professor of Epidemiology in the Fielding School of Public Health. Dr. Klausner earned his Medical Degree from Cornell University Medical College with Honors in Research. He completed his Residency in Internal Medicine at the New York University—Bellevue Hospital Center. Dr. Klausner earned his Master’s in Public Health with a focus on International Health and Epidemiology at the Harvard School of Public Health. After that training, Dr. Klausner was an Epidemic Intelligence Service Officer at the Centers for Disease Prevention and Control. Dr. Klausner completed his Fellowship in Infectious Diseases at the University of Washington, Seattle. Dr. Klausner’s research interests are in applied epidemiology and the prevention and control of infectious disease s of public health importance like HIV, STDs, TB and cryptococcal infections. Dr. Klausner has a particular interest in the use of technology—information, digital, and laboratory—to facilitate access to treatment for disadvantaged populations. Dr. Klausner has been funded by the NIH, CDC, private pharmaceutical and test manufacturers to study the benefits of new ways to find and treat infectious diseases. Dr. Klausner is a frequent advisor to the CDC, NIH and WHO and a popular public speaker. Dr. Klausner is a highly sought after mentor who has trained dozens of fellows, residents and students of medicine and public health.
|Michael Klepser, PharmD, FCCP, FIDP||Ferris State University|
Professor, College of Pharmacy
Dr. Klepser received his Doctor of Pharmacy from the University of Michigan College of Pharmacy in 1992. He has also completed a pharmacy practice residency at Detroit Receiving Hospital and University Health Center and a fellowship in infectious diseases at Hartford Hospital in Hartford, Connecticut. Dr. Klepser has been a Professor of Pharmacy at Ferris State University. Dr. Klepser’s research interests include CLIA-waived point-of-care tests, influenza, and health economics. Dr. Klepser has published extensively on these topics and has more than 130 peer-reviewed manuscripts to his credit
|Donald Klepser, PhD, MBA||University of Nebraska Medical Center|
Associate Professor and Vice Chair, Pharmacy Practice
Donald G. Klepser, PhD, MBA, is Associate Dean for Academic Affairs at the University of Nebraska Medical Center College of Pharmacy. He has PhD in Pharmaceutical Socioeconomics from the University of Iowa, an MBA from the University of Minnesota’s Carlson School of Management, and a Bachelor’s degree in Communications from the University of Michigan. He has studied the use of POC testing in community pharmacies for the past 11 years and is currently the primary investigator on grants to develop community pharmacy practice models for managing diseases such as HIV, diabetes, hypertension, influenza, and group A Streptococcus. Dr. Klepser serves as a consultant to both diagnostic test manufacturers and pharmacies seeking to implement POC testing in pharmacies.He is also the primary investigator on grants to better understand how state and local health departments perceive the role of pharmacists conducting POC tests.
|Thomas Kluz, MS||Qualcomm Ventures|
General Partner, dRx Capital; Head, Healthcare Investing
Thomas is the head of health care investing at Qualcomm Ventures where he focuses on digital health care companies. Thomas is also a General Partner at dRx Capital, which is a joint venture investment company launched by Novartis and Qualcomm with a capital commitment up to $100M. As part of these roles, Thomas strives to catalyze the success of digital medicine products, services and business models by investing in high-growth, technology companies. Prior to Qualcomm Ventures, Thomas was an investment professional at Providence Ventures, the venture capital arm at one of the nation’s leading healthcare delivery networks, Providence St. Joseph Health. Prior to Providence Ventures, Thomas was part of the strategic finance / strategic investing team at Cambia Health Solutions, the private equity sponsor for Regence Blue Cross Blue Shield, a nationally recognized health insurer committed to transforming healthcare. As part of his role at Cambia, Thomas had an observer seat on the Fund Management Team (FMT), the formal governing body established by the company to approve all VC, PE and M&A deals. Thomas was also a direct investment professional at Adams Street Partners where he supported the partnership on venture capital and growth equity opportunities. Thomas holds his Master of Science in Medical Informatics and a Bachelor of Science in Biomedical Engineering from Northwestern University where he is a published author in the Journal of Surgical Oncology..
|Walter Koch, PhD||Roche Molecular Diagnostics|
Vice President, Head, Global Research
Walter H. Koch, PhD is Vice President and Head of Global Research for Roche Molecular Systems. He is responsible for all research and early development activities, including biomarker discovery and validation, the development of new molecular technologies with diagnostics potential, and expanding the use of PCR for clinical applications in the areas of infectious diseases, genetics, Oncology companion diagnostics and “liquid biopsy” cancer tests. Prior to joining Roche he held several positions at the US FDA, including Acting Lab Chief of Immunochemistry in CBER’s Division of Transfusion Transmitted Disease. He received a BS in Chemistry from Memphis State University, a PhD in Toxicology and Pharmacology from the University of Tennessee Health Science Center, and was a Postdoctoral Fellow at the Johns Hopkins University School of Public Health.
|Gerald Kost, MD, PhD, MS, FAACC||University of California, Davis|
Director, Point-of-Care Testing Center for Teaching and Research (POCT•CTR), Emeritus Professor, School of Medicine
Dr. Kost studied Engineering at Stanford University (BS, 1967) and in Venezuela, then received the Master’s degree in Engineering-Economic Systems (EEP) from Stanford prior to entering Medical Scientist MD-PhD training at the University of California (UC). He received his PhD in Bioengineering (NIH Bioengineering Traineeship) from UC San Diego and his MD from UC San Francisco. He was elected to Mu Alpha Theta (mathematics), Phi Kappa Phi (scholarship), and Sigma Xi (science) Honor Societies. Dr. Kost’s clinical residency included Internal Medicine and Neurology at UCLA, and Laboratory Medicine at the University of Washington, Seattle, where he was Chief Resident and a postdoctoral researcher with Dr. Jim Bassingwaighte in Bioengineering. Dr. Kost was boarded in Clinical Pathology by the American Board of Pathology. At UC Davis for nearly 30 years, Dr. Kost is Director of Point-of-Care Testing and Clinical Chemistry for the UCD Health System. He is a tenured Professor in the Department of Pathology and Laboratory Medicine, the Quality Program Chair, and faculty in Biomedical Engineering and Comparative Pathology.
|Prachi Kothari, JD||Memorial Sloan Kettering Cancer Ctr|
Assistant Attending, Department of Pediatrics, Memorial Sloan Kettering Cancer Center
Prachi Kothari, DO received her medical degree from Nova Southeastern University. After completing pediatric residency at the University of Connecticut and pediatric hematology oncology fellowship at the combined programs at Memorial Sloan Kettering Cancer Center and New York Presbyterian-Hospital, Weill Cornell Medicine, she is presently a clinical instructor in the department of pediatrics at Memorial Sloan Kettering Cancer Center. She is also working in the Tsui Laboratory under the mentorship of Dr. Dana Tsui on understanding the feasibility and utility of noninvasive molecular profiling with cfDNA in patients with pediatric solid tumors. Her research projects have allowed her to now work alongside the clinical teams to implement the use of cfDNA analysis into the routine workflow allowing for real-time molecular profiling.
|Serguei Kozlov, PhD, MBA, PMP||NIH NCI|
Principal Scientist/PM, Team Leader PTO, Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research (NCI)
Internationally recognized expert in advanced methodologies for developing genetically and biologically engineered preclinical murine disease models for studies of the molecular mechanisms of carcinogenesis, tumor immune response, immune surveillance, and inflammation, mechanisms of drug resistance, implication of cancer stem cells, etc.; and to explore such models for preclinical drug development, disease systems analyses and biomarker discovery. Initiated, supervised, and successfully conducted multiple research projects and independent large-scale research and development programs aimed at investigation of molecular mechanisms governing carcinogenesis, biomarker discovery and preclinical drug evaluation in various mouse models. Oversees the preclinical operations at the Frederick National Laboratory Center for Advanced Preclinical Research – an innovative preclinical cancer modeling and drug development initiative based on genetically engineered murine models – with senior management responsibilities. Co-authored over 60 scientific papers, book chapters and original works in peer-reviewed journals.
Director, IBM Watson AI XPRIZE
Devin Krotman serves as the Director of both the IBM Watson AI XPRIZE and Global Learning XPRIZE. In this capacity for the last three years, Mr. Krotman oversees all complex operational aspects of these large programs - including, but not limited to project management, fiscal management, knowledge management, and risk management. Mr. Krotman is passionate about tackling the world’s grandest challenges from education to disaster prediction and firmly believes technology will help humanity get there. With nearly a decade of experience in management consulting prior to XPRIZE, Devin focuses on leveraging his problem-solving experience when it comes to helping run XPRIZE’s large scale competitions focused on innovative technology. Mr. Krotman holds a Project Management Professional (PMP) certification from the Project Management Institute. He also holds Bachelor of Science in Public Administration and Master of Public Administration degrees, both from James Madison University.
|Ravi Kuppuraj, PhD||Philips Lifeline|
Head, Connected Sensing and Wearables Venture
Ravi heads the Connected Sensing and Wearables Venture (CSV) at Philips. Ravi is a medical industry entrepreneur, with over 20 years of experience in patient monitoring, and healthcare IT. Prior to CSV, Ravi co-founded multiple startup companies in remote and cloud computing-based wearables monitoring. Ravi also served as the Vice President of Research and Development at Draeger Medical, a global powerhouse in patient monitoring, anesthesia delivery, and respiration, and headed R&D efforts at SpaceLabs Medical, in Seattle, where he was instrumental in driving the development of key technologies and products in patient monitoring solutions and was the General Manager for their India operations. In addition, Ravi holds an MBA from the University of North Carolina at Chapel Hill, a PhD and MS in biomedical engineering from Louisiana Tech University and University of Miami respectively, and a BSEE from Bangalore University.
Vice President, Technology
No bio available
|Michael Latauska||Boehringer Ingelheim Pharmaceuticals Inc|
Director, Digital Health
No bio available
|Michael Lawrence, PhD||Massachusetts General Hospital|
Assistant Professor of Pathology, Harvard Medical School; Assistant Geneticist
Dr. Lawrence's research group focuses on understanding the many ways that cancer can arise from DNA mutations, using computation as a powerful microscope through which to study the processes of DNA damage and repair, gene expression and genome replication, and cancer driver genes. Over our lifetimes, DNA slowly accumulates mutations due to environmental toxins and radiation, as well as from natural occasional copying errors. The vast majority of mutations have little or no effect on a cell. But out of all possible mutations, a few may hit exactly the right place in the genome where they can act as a "driver mutation," pushing the cell toward aggressive growth and tumor formation. Sequencing the DNA in a tumor reveals not only its driver mutations, but also all the other "passenger mutations" that were present in the tumor-initiating cell. The Lawrence Lab integrates across data from clinical samples and laboratory models, seeking insights about cancer from both driver and passenger mutations.
|Nathan Ledeboer, PhD||Medical College of Wisconsin|
Professor and Vice Chair, Pathology and Medical Director
Dr. Ledeboer received his BA Degree from Dordt College in 2000 and his PhD Degree in Microbiology from the University of Iowa in 2005. Following two years of fellowship training in clinical and public health microbiology at Washington University School of Medicine in Saint Louis, MO, he became an Assistant Professor of Pathology at the Medical College of Wisconsin and Medical Director of Clinical Microbiology and Molecular Diagnostics at Froedtert Hospital and Dynacare Laboratories in Milwaukee, WI where he has remained for more than 5 years. In addition to his service activities as director of clinical microbiology and molecular diagnostics at a large academic medical center, Dr. Ledeboer continues to develop his research career. His research endeavors, particularly in the area developing diagnostic tools for infectious diseases, have led to numerous publications in peer-reviewed journals. He has been Chairman of Public and Professional Affairs for the South Central Association for Clinical Microbiology and served on the American Society for Microbiology’s Clinical Microbiology Task Force. Dr. Ledeboer is currently a member of the American Board of Medical Microbiology Exam committee, a member of the Committee on Postgraduate Educational Programs through the American Society for Microbiology, and is the microbiology scientific program chair for The Association for Mass Spectrometry: Applications to the Clinical Laboratory. He is currently a member of the editorial board of the Journal of Clinical Microbiology and serves as an ad hoc reviewer for numerous other journals in infectious diseases and clinical microbiology. He has delivered nearly 100 invited lectures in various medical-scientific educational forums worldwide and has served as an investigator on more than 75 funded research projects. In 2011, he received the distinguished Siemens Young Investigator Award from the American Society for Microbiology.
|Fred Lee, MD, MPH||AWS|
Head, Health Care and Life Sciences, Business Development
Dr. Lee provides physician leadership in business development for AWS Data Exchange, a new service that makes it easy to find and subscribe to third-party data in the cloud, in a regulatory compliant, ethically sound, economically sustainable, and secure cloud-native fashion. Fred’s personal passion is accelerating the digitally- driven transformation of healthcare to a predictive, preventive, personalized, and participatory state.
|Abraham Lee, PhD||Univ of California Irvine|
Professor, Biomedical Engineering
Professor Lee joined UCI from the National Cancer Institute, where he served as Senior Technology Advisor in the Office of Technology and Industry Relations (OTIR) (4/2001-12/2001). Specifically, Dr. Lee was responsible for identifying new opportunities in interagency collaborations, new strategies to promote technology maturation, and provide expert advice on promoting technology development within NIH. Before joining NCI, Dr. Lee was a program manager at the Defense Advanced Research Projects Agency (DARPA) (1999-2001) in the Microsystems Technology Office (MTO). At DARPA, he started the $59M BioFlips (Bio-Fluidic Chips) Program and was one of three founding program managers managing the "Fundamental Research at the Bio:Info:Micro Intersection" program. During this tenure, he gave invited talks extensively and was instrumental in shaping the nation’s technical directions in micro-fluidics and BioMEMS.
|Alpha Lee, PhD||University of Cambridge|
Dr. Alpha Lee is the Winton Advanced Fellow in Physics at the University of Cambridge. He is focused on integrating physics, statistics and machine learning. Before Cambridge, Alpha was the George F. Carrier Fellow in Engineering and Applied Sciences at Harvard. He has a PhD in mathematics, an MS in mathematical modeling and scientific computing from Oxford and a BS in Chemistry from Imperial College London.
|SuIn Lee, PhD||Univ of Washington|
Associate Professor, Paul G. Allen School of Computer Science & Engineering
Prof. Su-In Lee is an Associate Professor in the Paul G. Allen School of Computer Science & Engineering and an Adjunct Associate Professor in the Departments of Genome Sciences, Electrical Engineering, and Biomedical Informatics and Medical Education at the University of Washington. She completed her PhD in 2009 at Stanford University with Prof. Daphne Koller in the Stanford Artificial Intelligence Laboratory. Before joining the UW in 2010, Lee was a visiting Assistant Professor in the Computational Biology Department at Carnegie Mellon University School of Computer Science. She has received the National Science Foundation CAREER Award and been named an American Cancer Society Research Scholar. She has received generous grants from the National Institutes of Health, the National Science Foundation, and the American Cancer Society.
|Annette Leon, PhD FACMG||Color Genomics Inc|
Head, Clinical Reporting
Dr. Annette Leon is a medical geneticist board certified by the American Board of Medical Genetics and Genomics and Head of Clinical Reporting at Color. She completed her fellowship in Clinical Molecular Genetics and Genomics and Clinical Cytogenetics and Genomics at Harvard Medical School’s Genetics Training Program. Dr. Leon also received a PhD in BioPhysics and Computational Biology at the University of Illinois at Urbana. Her clinical work currently focuses on improving access and utilization of genomic medicine at a population level, bringing more than 10 years of experience in medical genetics.
Technical Development Engineer @ Genentech and Vice President of Startegy & Corporate Development @ Research to the People, my enjoyment and expertise lies at the intersection of biomedicine and computation. Currently focused on technology evaluation, CMC strategy and corporate development for multi-omic analytics and individualized therapeutics. My prior experience spans tissue engineering, biologics development and life science consulting. A proud first-generation college student, I am passionate about improving education outcomes, evolving diversity practices and reducing health inequities.
|Alexander Lex||Univ of Utah|
I am an Assistant Professor of Computer Science at the Scientific Computing and Imaging Institute and the School of Computing at the University of Utah. Together with Miriah Meyer, I run the Visualization Design Lab where we develop visualization methods and systems to help solve today’s scientific problems. Before joining the University of Utah, I was a lecturer and post-doctoral visualization researcher at Harvard University. I received my PhD, master’s, and undergraduate degrees from Graz University of Technology. In 2011 I was a visiting researcher at Harvard Medical School. I am the recipient of an NSF CAREER award and multiple best paper awards or honorable mentions at IEEE VIS, ACM CHI, and other conferences. I also received a best dissertation award from my alma mater. I co-founded Datavisyn, a startup company developing visual analytics solutions for the pharmaceutical industry, and the Caleydo project, an open source visualization framework for biomolecular data.
|Ying Li, PhD||Bristol-Myers Squibb|
Lead IT Business Partner – Precision Medicine, Translational Medicine IT
No bio available
|Michael Liebman, PhD||IPQ Analytics LLC|
Michael N. Liebman, PhD, is the Managing Director of IPQ Analytics, LLC and Strategic Medicine, Inc after serving as the Executive Director of the Windber Research Institute (now ChanSoon-Shiong Institute for Molecular Medicine) from 2003-2007. He is an Adjunct Professor of Pharmacology and Physiology at Drexel College of Medicine and Adjunct Professor of Drug Discovery, First Hospital of Wenzhou Medical University and also Fudan University. Previously, he was Director, Computational Biology and Biomedical Informatics, University of Pennsylvania Cancer Center 2000-2003. He served as Global Head of Computational Genomics, Roche Pharmaceuticals and Director, Bioinformatics and Pharmacogenomics, Wyeth Pharmaceuticals, Director of Genomics for Vysis, Inc. He is a co-founder of Prosanos, Inc (now United BioSource) (2000). He was Associate Professor of Pharmacology and of Physiology/Biophysics at Mount Sinai School of Medicine. He serves on 14 scientific advisory boards and the Board of Directors of the Nathaniel Adamczyk Foundation in Pediatric ARDS and Innovene Pharmaceuticals. Michael is Chair of the Informatics Program and also Chair of Translational Medicine and Therapeutics for the PhRMA Foundation and a member of their Scientific Advisory Board. His research focuses on computational models of disease progression that stress risk detection, disease processes and clinical pathway modeling, and disease stratification from the clinical perspective. He utilizes systems-based approaches and design thinking to represent and analyze risk/benefit analysis in pharmaceutical development and healthcare.
|Keith Ligon, PhD||Brigham & Womens Hospital|
Associate Professor, Pathology
Dr. Ligon is a Physician-Scientist with expertise in neuropathology and oncology focused on improving the diagnosis and treatment of cancer. He attended medical school and received his PhD at the University of Texas-Houston Medical School and the MD Anderson Cancer Center. Currently he is an Associate Professor of Pathology at Harvard Medical School with joint appointments at the Dana-Farber Cancer Institute, the Broad Institute, and Brigham and Women’s Hospital (BWH). He is the Chief of Neuropathology at BWH/DFCI and the Director of the Center for Patient Derived Models (CPDM) at DFCI. His research and clinical activities have improved the scientific understanding of brain tumors. He is directly involved in the training of medical and graduate students, postdoctoral fellows, residents, and faculty. Several of the methods he has developed in his research have been implemented in the clinical pathology lab to improve patient diagnosis. He has also led efforts to train neuropathologists in the utilization of genomic tests in practice and led genomically informed clinical trials development at the local and national consortium levels.
|Steven Lin, MD||Stanford Univ|
Vice Chief, Technology Innovation
Dr. Lin is an expert clinician, educator, researcher, and administrator in the specialty of family medicine. He earned his MD from Stanford University School of Medicine and completed his medical training at Stanford’s family medicine residency program at O’Connor Hospital. Dr. Lin is certified by the American Board of Family Medicine and is an active member of the Society of Teachers of Family Medicine. He has received numerous national awards and is recognized among the top family physicians in the United States. Dr. Lin is the Medical Director of Stanford Family Medicine and the Vice Chief for Technology Innovation in the Division of Primary Care and Population Health at Stanford. Dr. Lin is the founder of the nationally recognized O’Connor-Stanford Leaders in Education Residency Program (OSLER), co-founder of the Stanford Healthcare Innovations and Experiential Learning Directive (SHIELD) and founding director of the Stanford Medical Scribe Fellowship (COMET). Dr. Lin is the author of over 200 scholarly works and conference presentations. His research covers a broad range of primary care topics. His current focus is on artificial intelligence in healthcare. Dr. Lin is an expert consultant and mentor to health technology companies in the United States, Canada, Europe, and Asia.
Senior Director, Medical Affairs
Michael J. Loeffelholz, PhD, D(ABMM) is Senior Director, Medical Affairs at Cepheid, and Adjunct Professor of Pathology at the University of Texas Medical Branch (UTMB), Galveston. He received a PhD in microbiology from Ohio University, Athens, OH in 1987. After completing a post-doctoral fellowship in medical and public health microbiology at the University of Rochester in 1990, he was a Senior Scientist at Roche Molecular Systems from 1990-1995. From 1995-2008 Dr. Loeffelholz held leadership positions in public health laboratories and private reference laboratories. From 2008-2018 he held the rank of Associate Professor, then Full Professor in the Pathology Department at UTMB, and Medical Director of the Clinical Microbiology Laboratory. Dr. Loeffelholz joined Cepheid in 2018. He is an editor of the Journal of Clinical Microbiology. He currently serves as the Secretary/Treasurer of the Pan American Society for Clinical Virology and is a member of the Board of Scientific Counselors to the Centers for Disease Control and Prevention (CDC) Office of Infectious Diseases. He previously served on the Association of Public Health Laboratories (APHL) Board of Directors. Dr. Loeffelholz has authored over 80 research and review papers and book chapters.
|Alan Louie, PhD||IDC Health Insights|
Research Director, Life Sciences
Dr. Louie brings more than 32 years of technology, product and strategy development from across the life science industry. Previously, Dr. Louie led applied biotechnology programs as Senior Manager at Arthur D. Little, Inc. In this role, he managed laboratory-based technology development programs, as well as provided content expertise to life science and healthcare strategy projects. Over his career, Dr. Louie was responsible for the development and commercialization of more than 30 products for a variety of industries, including many first-in-class product offerings.
|Matthew Lungren, MD, MPH||Stanford Univ|
Associate Director, Stanford Center for Artificial Intelligence in Medicine and Imaging
Dr. Lungren serves as Assistant Professor of Radiology at Stanford University. The goal of his research is to advance both predictive imaging outcomes modeling and medical imaging machine vision through machine learning and other information technologies. As faculty in the Langlotz biomedical informatics research laboratory he collaborates on novel machine learning and natural language processing algorithms that provide intelligent assistance for comparitive effectiveness research, medical imaging utilization, and clinical medical imaging decision support.
|Mitchell Lunn, MD, MAS, FASN||Stanford Univ|
Assistant Professor, Medicine
Mitchell (Mitch) R. Lunn, MD, MAS, FASN (he/him/his) is an Assistant Professor in the Division of Nephrology of the Department of Medicine at Stanford University School of Medicine. As an internist and nephrologist with a strong interest in technology and sexual and gender minority health, Mitch’s research is designed to characterize the health and well-being of these populations. Sexual and gender minority (SGM) people – which primarily includes members of the lesbian, gay, bisexual, transgender, and queer (LGBTQ) communities – face numerous health and healthcare disparities. Through the use of existing and emerging technologies, Mitch focuses on improving understanding of the factors that positively and negatively influence SGM health including research on SGM health disparities, SGM societal experiences (in and out of health care), provider education about SGM health, and institutional climate towards SGM people. As a gay man and active researcher in SGM health for over a decade, Mitch brings vital experience and scholarship in engaging diverse, vulnerable, and hard-to-reach populations using technology-based and traditional methodologies. Mitch is the co-director of PRIDEnet, a participant-powered research network of SGM people that engages SGM communities at all stages of the biomedical research process: research question generation and prioritization, study design, recruitment, participation, data analysis, and results dissemination. PRIDEnet accomplishes its goals through a highly active Participant Advisory Committee and a Community Partner Consortium comprised of 41 SGM-serving health centers, community centers, and service/advocacy organizations across the country. Mitch is also the co-director of The PRIDE Study, a national, online, prospective, longitudinal general health cohort study (launched May 2017) of over 13,200 SGM individuals that employs innovative technologies to bridge research gaps in the health of these medically underserved and vulnerable populations. The PRIDE Study’s state-of-the-art web-based research platform enables robust participant recruitment, cohort management, real-time cohort statistics, comprehensive survey administration, facile deployment of studies to cohort segments, and linkage with mHealth devices.
|Frank Lynch, PhD||Discovery Life Sciences|
Executive Vice President, IHC Services
For more than 30 years Frank Lynch has been a pioneer in immunohistochemistry applications in research & clinical studies. He co-founded QualTek Molecular Laboratories & developed an IHC services platform built around this powerful tool that allows for the understanding of expression & localization of specific proteins with cell & sub-cellular specific resolution. He received his PhD from Rutgers University/UMDNJ, where he researched dUTPase and its role in patient response to 5FU in colorectal cancer.
|Duncan MacCannell, PhD||Centers for Disease Control and Prevention|
CSO, Office of Advanced Molecular Detection
Duncan MacCannell is the chief science officer for the CDC’s Office of Advanced Molecular Detection (OAMD), where he helps coordinate the implementation and support of pathogen genomics, bioinformatics, high-performance computing and other innovative laboratory technologies across the CDC’s four infectious disease centers. With a broad focus on public health laboratory science and strategic innovation, he manages the agency's high performance computing center of excellence, and works to integrate standardized, sustainable capacity for advanced laboratory technologies and scientific computing into routine public health practice. As a public health microbiologist and molecular epidemiologist, Duncan has worked with the PulseNet program on the development and validation of next-generation subtyping and characterization methods for Shiga-toxin producing Escherichia coli (STEC), as a general subject matter expert in bacterial molecular epidemiology and antimicrobial resistance, and as the CDC laboratory surveillance lead for healthcare-associated pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile. His current research interests include the application of comparative pathogen genomics and metagenomics to public health microbiology, and the development, validation, and implementation of molecular diagnostics, next-generation straintyping and bioinformatics for pathogen identification, outbreak investigation and large-scale molecular surveillance.
|Allison Mallory, PhD||Stilla Technologies|
Director, R&D Molecular Biology
With a PhD in in Molecular, Cellular and Developmental Biology, Allison pursued post-doctoral work on the function and developmental roles of microRNAs at the Whitehead Institute of MIT. After moving to France, she worked at both INRA and the Curie Institut investigating noncoding RNAs in both plants and vertebrates. After consulting at a Paris-based single-cell sequencing start-up, Allison joined Stilla Technologies early in 2019 as the director of the R&D Molecular Biology team, where she and the R&D team work to push the limits of digital PCR using NaicaTM Crystal™ Digital PCR technology.
|Maksim Mamonkin, PhD||Baylor College of Medicine|
Assistant Professor, Pathology & Immunology, Center for Cell and Gene Therapy
Dr. Mamonkin is a faculty member at the Center for Cell and Gene Therapy, Baylor College of Medicine. The main research focus of his laboratory is studying the immunobiology of CAR-engineered T cells and developing adoptive cell therapies for hematologic malignancies. Dr. Mamonkin has developed and optimized for clinical evaluation CAR T cell platforms for T-cell malignancies and AML and serves as a PI on several clinical trials of CAR T cells at Baylor.
|Vani Mandava||Microsoft Research|
Director, Data Science Outreach
Vani Mandava is a Director of Data Science at Microsoft Research at Redmond with over a decade of experience in engineering teams designing and shipping software that in use by millions of users across the world. She is passionate about enabling academic researchers and institutions develop technologies that fuel data-intensive scientific research using advanced techniques in data management, data mining, especially leveraging Microsoft cloud and AI platform. She has enabled the adoption of data mining best practices in various v1 products across Microsoft client, server and services in MS-Office, Sharepoint, Online Services (Bing Ads) organizations and in the Academic Search service. She co-authored a book ‘Developing Solutions with Infopath’ and holds patents in service engineering. She leads Microsoft Research Outreach efforts at Data Science Institutions in US universities. She co-chaired KDD Cup 2013 and partners with many academic and government agencies including NSF supported Big Data Innovation hub effort, a consortia coordinated by top US data scientists and expected to advance data-driven innovation nationally in the US. She is currently leading the microsoftopendata.com project, a cloud based open data repository.
|Christine Manta, MS, RD||Elektra Labs|
Research Project Manager
Christine Manta (@christinemanta) is the Research Project Manager at Elektra Labs. Previously, Christine worked on research teams at Christiana Care’s Value Institute, University of Pittsburgh Medical Center (UPMC) and Children’s Hospital of Philadelphia (CHOP). She was introduced to the digital medicine field via her work with Clinical Trials Transformation Initiative (CTTI)’s systematic review of feasibility studies using mobile technologies in clinical research. She has a master’s in nutrition and is Registered Dietitian. Christine also serves as a Research Lead at Digital Medicine Society (DiMe), a 501(c)3 professional society for digital medicine practitioners.
|Leidong Mao, PhD||Univ of Georgia|
Professor, School of Electrical and Computer Engineering
Leidong Mao is a Professor in the School of Electrical and Computer Engineering at the University of Georgia in Athens, GA. He received his PhD in electrical engineering from Yale University. He is interested in developing new microfluidic technologies for biological or biomedical applications.
|Narasimha Marella, PhD||Loxo Oncology Inc|
Director, Biomarker Operations
Narasimha Marella graduated in Jan 2009 with a PhD in Biological Sciences from University at Buffalo, Buffalo NY. He has a master’s degree in biotechnology and an undergraduate degree in microbiology from India. His previous research interests were in investigating the three dimensional structural and functional architecture of the human nucleus in normal and cancer cell types. Dr. Marella has authored six peer reviewed articles and serves a reviewer for a couple of scientific journals. Currently, Dr. Marella leads the biomarker operations across Loxo Oncology’s clinical trial portfolio and involved in diagnostic development. Prior to Loxo, Dr. Marella was at Cancer Genetics (CGI) for 10 years in various roles including leading lab operations, managing CGI’s Clinical trial initiative (SELECT ONE) along with members from the research and clinical lab departments.
|Peter Marks, MD, PhD||FDA CBER|
Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in January 2016.
|Albine Martin, PhD||Johns Hopkins Univ|
Executive in Residence
Dr. Albine Martin brings more than 20 years of technology commercialization, portfolio management and corporate development experience with three public companies representing the biotechnology, diagnostics, genomics and life sciences sector. She also serves as a member of Active Angels, where she syndicated early stage investments and a member of the independent review panel for NSF Phase1/2. She currently serves as COO at Precision Biologics, a clinical development oncology company with a companion diagnostic program. Precision is a clinical stage oncology company and is advancing its first program for colorectal and pancreatic cancer following the acquisition of assets from Neogenix Oncology.